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Pancreatic cancer is a devastating disease that leaves patients with a very poor 
prognosis and few therapeutic options.  Many of the treatment options available are the 
same that have been used for almost 2 decades.  There is a dire need for both novel 
treatments for this disease as well as novel strategies of treatment.  This body of work 
will introduce and provide evidence in support of a novel combination therapy for 
pancreatic cancer treatment, a novel strategy of modifying currently used 
chemotherapeutics for pancreatic cancer therapy, and a novel transgenic preclinical 
mouse model of pancreatic cancer.  Sabutoclax, an antagonist of the anti-apoptotic Bcl-
 xiv 
2 proteins, and Minocycline, a commonly used antibiotic, show potent synergy when 
used in combination in both pancreatic cancer cells and in multiple immune-deficient 
and immune-competent mouse models of pancreatic cancer.  Sabutoclax alone is 
capable of inducing cell cycle arrest and apoptosis in cells and its cytotoxicity is 
enhanced significantly when combined with Minocycline.  This combination results in 
the loss of Stat3 activation both in vitro and in vivo, which is essential for its toxicity.  It 
also inhibits tumor growth and prolongs survival in the KPC transgenic mouse model of 
pancreatic cancer.  Also presented here are studies that demonstrate efficacy in vivo of 
modified versions of Gemcitabine and Paclitaxel.  These drugs are linked to a peptide 
that shows specificity for the EphA2 receptor, which is overexpressed on the surface of 
pancreatic cancer cells and only minimally on normal cells.  This peptide results in 
increased cellular uptake of drug, as it is bypassing its normal mechanism of entry.  
These normal mechanisms are often dysregulated in cancer, leading to decreased 
uptake and drug resistance.  The use of these modified drugs show significantly 
increased tumor growth inhibition as compared to the parent drug alone. Finally, we 
provide data on the characterization of a novel transgenic mouse model of pancreatic 
cancer.  This model, the Pan Met View (PMV) mouse, combines the commonly used 
KPC transgenic mouse model of pancreatic cancer and a mouse that expresses a 
Luciferase reporter gene under the control of the cancer-specific promoter, CCN1.  Our 
data shows that double transgenic PMV mice can now be used to follow primary tumor 
and metastasis development in real time by Bioluminescent imaging (BLI) through 
disease progression and potentially therapy. This strategy will enhance the use of 
genetically engineered mouse models (GEMMS) to study cancer initiation and 
 xv 
progression with potential to non-invasively monitor therapy.  These chapters present 
novel and exciting data that have the potential to open multiple avenues of translational 
study and result in significant advances in pancreatic cancer therapy.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 1 
Chapter 1: Introduction 
 
I. Pancreatic Cancer  
 
Pancreatic ductal adenocarcinoma (PDAC) is an extremely aggressive cancer 
that is estimated to result in over 39,000 deaths in the US in 2014 (NCI 2014).  It is 
currently the fourth most commonly diagnosed cancer and holds a 5-year survival 
rate of about 4% (1).  This poor prognosis results, in part, from a delayed diagnosis 
of the disease.  Patients experience few symptoms and those that they may 
experience tend to be vague in nature.  Abdominal pain, depression, weight loss, 
and loss of appetite are all commonly seen, though they are often overlooked until 
they become chronic issues.  Jaundice can be a symptom of pancreatic head 
tumors, which is much more telling of a significant underlying problem.  The 
consequence of this clinical presentation is that most patients have either locally 
advanced or metastatic disease at the time of diagnosis.  Risk factors for pancreatic 
cancer include a history of smoking, diabetes, chronic pancreatitis, and some 
inherited genetic mutations/familial diseases (2).  
II. Pancreatic Cancer Therapy   
 
Unfortunately, treatment options remain minimal for patients diagnosed with this 
aggressive disease.  Surgical resection is the only potentially curative treatment, but, 
due to delayed diagnosis, is only an option for approximately 15% of patients (2).  
Because of the anatomical location of the pancreas, even tumors discovered before 
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metastatic spread are usually not resectable.  Significant involvement of the tumor 
with surrounding vital organs and vessels, such as the celiac trunk, superior 
mesenteric artery/vein, and the hepatic artery, eliminate its ability to be surgically 
removed (2).  This tumor involvement, which can often eventually encase organs or 
vessels entirely, can often be a primary cause of death in these patients, a result of 
the rupture of vessels or impairment of normal function.   
Chemotherapy remains the most utilized option for patients with pancreatic 
cancer, though outcomes are still poor.  Gemcitabine remains the standard of care, 
even though it has been almost 2 decades since it was established to have a 
prolonged survival benefit as compared to Fluorouracil (3).  Despite this, Fluorouracil 
is still used in treatment regimens, as well as a number of novel combination 
therapies.  Folfirinox, a combination of fluorouracil, irinotecan, oxaliplatin, and 
leucovorin, has been shown to improve survival in patients with metastatic disease 
and is now being evaluated in patients with locally advanced tumors.  Additionally, 
the combination of Gemcitabine and nab-Paclitaxel (Abraxane) was also recently 
approved by the FDA for the treatment of metastatic pancreatic cancer after clinical 
trials showed significant survival advantages.  These two combination therapies are 
now considered standard of care for patients with metastatic disease.    Though 
radiotherapy is often incorporated into some treatment regimens and clinical trials, 
data regarding its efficacy remains somewhat controversial (2).   
 
III. Genetics of Pancreatic Cancer 
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The aggressive nature of the cancer and the resulting dismal prognosis for patients 
results, in part, from the vast array of molecular changes that occur during the 
development of pancreatic adenocarcinoma.  Pancreatic tumors are known to be 
chemoresistant as well and this resistance to therapy is often due to the many different 
genetic changes seen in pancreatic tumors. 
The development of a pancreatic adenocarcinoma follows a sequence of 
histological changes that turns a normal pancreatic epithelium into an invasive 
pancreatic adenocarcinoma.  This process has been classified into a series of pre-
invasive stages referred to as pancreatic intraepithelial neoplasia (PanIN) lesions 
(Figure 1).  These dysplastic ductal lesions range in number from PanIN I (low-grade 
lesion to PanIN 3 (high grade lesion or pancreatic ductal adenocarcinoma in situ).   
These progressive histological changes occur as the result of parallel underlying 
molecular changes.  It is these molecular changes that ultimately result in an invasive 
pancreatic adenocarcinoma.  It is also important to note that these changes occur at 
fairly specific time points throughout this progressive model and in a particular order.  
Additionally, not all pancreatic cancers will have the exact same molecular changes, 
further contributing to its inherent aggressive and chemoresistant nature.  Different 
tumors will often have different combinations of genetic mutations, chromosomal losses, 
etc.  This is why finding therapy to treat pancreatic cancers as a group remains so 
difficult.  Despite the vast number of potential molecular changes, there are a few that 
occur in a large number of pancreatic cancer cases.  
A. Major Oncogenes and Tumor Suppressors 
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One of the very first changes that occur in a normal pancreatic epithelial cell is the 
mutation of K-ras.  K-ras is part of the Ras family of proteins that is involved in signal 
transduction through the MAPK and PI3K/Akt pathways.  K-ras is mutated in over 90% 
of pancreatic cancers and primarily responsible for the initial transformation event in 
normal cells.  This mutation has been seen in codons 12, 13, and 61, with codon 12 
being the most frequently seen sight for K-ras mutations (4).  This oncogenic, early 
event results in constitutive activation of K- ras and is seen in PanIN 1 lesions through 
to invasive carcinoma.  K- ras mutation is seen in approximately 36% of PanIN-1A 
lesions, 44% of PanIN-1B lesions, and 87% of PanIN 2-3 lesions (5).  It should also be 
noted that pancreatic adenocarcinomas that arise in a patients with chronic pancreatitis 
tend to have lower frequencies of K-ras mutations, though the reason is not entirely 
clear (4). 
In vitro and in vivo studies have confirmed K-ras mutation as an early and 
initiating event in the development of PDAC.  Mouse models developed that express 
mutant K-ras in the pancreas result in the generation of ductal lesions resembling PanIN 
lesions (6).     
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Figure 1: Genetic Progression Model of Pancreatic Cancer.  Adapted from (7). 
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One of the next changes often seen affects the gene encoding p16, 
CDKN2A/INK4A.  p16 is a cell cycle checkpoint protein and can initiate G1-S phase 
arrest.  It is a very important protein in normal cell cycle function and is lost in around 
90% of pancreatic cancer cases.  Though p16 is lost in the majority of PDAC cases, the 
mechanism of its loss is not always the same.  Possible mechanisms of p16 loss 
include homozygous deletion of the CDKN2A/INK4A gene, intragenic mutation plus the 
loss of the 2nd allele, and epigenetic silencing through promoter methylation (4).  Loss of 
p16 is considered a fairly early to intermediate event in the development of PDAC.  
Around 30% of PanIN-1A and 1B lesions, 55% of PanIN 2 and 71% of PanIN 3 lesions 
show loss of p16 (4).  Additionally, as seen with K-ras mutations, the frequency of loss 
of this tumor suppressor is decreased in cancer cases resulting from chronic 
pancreatitis.   
The next big molecular event seen in the progression to PDAC is the inactivation 
of the TP53 gene.  p53 function is lost in approximately 50-75% of pancreatic 
adenocarcinomas and occurs much later in PDAC development, with changes in p53 
not usually seen until the stage of a PanIN-3 lesion.  It is normally involved in cell cycle 
regulation and loss of it results in inappropriate cell cycle progression.  It is also thought 
to contribute to the overall genomic instability seen in pancreatic cancer.  In the majority 
of cases, p53 function is lost through intragenic mutation of one allele and loss of the 
second.   
Another late event that occurs in PDAC development is the loss of the 
DPC4/SMAD4/MADH4 gene.  The SMAD4 protein is involved in signal transduction 
downstream of TGF-β and plays a role in growth inhibition.  Loss of this tumor 
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suppressor gene therefore results in uncontrolled proliferation.  This gene is lost in 50-
90% of pancreatic cancers (8).  SMAD4 is expressed in lower and intermediate stage 
PanIN lesions and lost in 31-41% of PanIN-3 lesions, supporting this as a later 
occurring event (4).   
These four changes are the most significant and frequent molecular events seen 
in the development of pancreatic adenocarcinoma.  Animal models developed by 
different groups have shown that combinations of K-ras mutations and loss of these 
tumor suppressor genes result in the development of a pancreatic adenocarcinoma in 
mice that closely resembles human PDAC (9).   
B. Stat3 
 
Stat3 is a transcription factor that is a part of a large family of signal transducer 
and activator of transcription (STAT) proteins.  This family consists of seven proteins 
and they each carry six conserved protein domains.   These domains consist of a 
tetramerization domain, a N-terminal coil-coil domain, a DNA-binding domain, a linker 
domain, a SH2 domain, and a C-terminal transactivation domain (10).  These domains 
play important roles in the normal function of Stat3 and can have clinical implications as 
well. 
In a normal cell, Stat3 resides predominantly in the cytoplasm.  When ligand 
binding activates tyrosine receptor kinases, they dimerize and undergo 
transphosphorylation.  This activates a series of phosphorylation steps that can involve 
a variety of different intracellular kinases.  These phosphorylations lead to the 
recruitment of proteins that are involved in signal transduction pathways.  Stat3 is one 
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such protein.  It gets recruited to the receptor complex via its SH2 domain and then it 
becomes phosphorylated (11).  Stat3 has a tyrosine residue at position 705 and a 
serine residue at position 727, both of which can be phosphorylated.  In most cases, it is 
a tyrosine kinase involved in this process and, as a result, tyrosine 705 of Stat3 is 
usually the phosphorylation site involved in this protein’s activation.  While multiple 
kinases are able to phosphorylate and subsequently activate Stat3, most times it is the 
JAK family of kinases that carry out this job (12). 
Once Stat3 is phosphorylated, it forms a dimer with another Stat3 monomer 
through the binding of the phosphorylated tyrosine of one monomer to the SH2 domain 
of the second.  This forms an active Stat3 dimer.  This dimer is now able to translocated 
into the nucleus, where it function as a transcription factor, binding DNA and regulating 
gene expression of its targets (10). 
As a transcription factor, Stat3 can regulate the expression of its transcriptional 
targets.  It is through the regulation of these targets that Stat3 can be responsible for the 
cancer supporting phenotype seen when it becomes constitutively active.  Many of the 
transcriptional targets of Stat3 play pro-survival roles in the cell and, when Stat3 
signaling goes unregulated, these targets become active players in cancer 
development.  Some of these targets are important specifically in pancreatic cancer and 
include (but are not limited to) the antiapoptotic members of the Bcl-2 family, Cyclin D1, 
and VEGF (13).  
Targeting Stat3 in pancreatic cancer has further shown the importance of this 
protein in this disease.  Yang, et. al. showed that knocking down Stat3 via lentivirus 
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mediated RNAi in a pancreatic cancer cell line resulted in decreased cell growth, 
decreased expression of VEGF and MMP-2, and decreased invasive abilities in a in-
vitro invasion assay (Yang, G. et. al. 2009).  Lewis, et. al. utilized a different approach 
by developing oligonucleotides complementary to binding sequences of Stat3.  They 
showed that these oligos were able to induce apoptosis in a pancreatic cancer cell line 
and that they could decrease expression of Stat3 target CD46.  CD46 is a protein that 
can protect tumor cells from complement-mediated cytotoxicity (Lewis, HD, et. al. 2008). 
These two methods target Stat3 expression and activity.  Other methods, such 
as the development of peptide inhibitors and small molecule inhibitors, take a look at the 
activation of the Stat3 monomer and use this process to develop inhibitors.  As 
mentioned previously, activated Stat3 monomers form dimers via their SH2 protein 
domains.  It is this dimer that can translocate to the nucleus and carry out its 
transcriptional function.  A strategy in targeting Stat3 has been to develop inhibitors that 
bind to this SH2 domain, prohibiting it from binding to another Stat3 monomer and 
forming a functional dimer.   
This was first accomplished by Turkson, et. al.  This group created the peptide, 
PY*LKTK (Y* = a phosphorylated tyrosine), that bound to the SH2 domain of a Stat3 
monomer.  However, like many firsts, this peptide did not exhibit good efficacy and 
required high doses to achieve results (Turkson, J. et. al. 2001).  Further derivatives 
were developed by multiple groups, but, as with many peptide inhibitors, the polarity of 
them and the transient nature of the phosphate groups resulted in problems 
(Haftchenary, S. et. al. 2011).  Ge, et. al. tried to address this problem by developing an 
unnatural amino acid meant to replace the phosphorylated tyrosine.  In this amino acid, 
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the phosphate group was replaced by an isoxazole carboxylic acid moiety.  The 
compound made with this new amino acid, ISS610, was a tripeptide that was shown to 
have moderate inhibitory effects against the SH2 domain of Stat3 and improved cell 
permeability (Ge, J. et. al. 2010). 
Many of the small molecule inhibitors of Stat3 aim to function in the same way as 
the peptide inhibitors, by targeting the SH2 domain of Stat3 and preventing 
dimerization.  However, small molecule inhibitors often have much greater efficacy than 
peptide inhibitors due to their more advantageous physiological properties.  For 
example, small molecule inhibitors are able to rapidly diffuse through cell membranes, a 
property not exhibited by peptide inhibitors.  Though there have been many Stat3 small 
molecule inhibitors developed, those discussed here will focus on two that have been 
studied in the context of pancreatic cancer, LLL12 and Cucurbitacin. 
LLL12 was developed by Lin, et. al. via a structural based approach.  It has been 
shown to bind directly to phosphorylated tyrosine 705 and exert a variety of inhibitory 
effects on cancer, but not on normal, cells.  In pancreatic cell lines, LLL12 was shown to 
reduce Stat3 DNA binding, induce apoptosis, and decrease mRNA and protein 
expression of Stat3 targets CyclinD1, Survivin, and Bcl-2 family anti-apoptotic proteins.  
Additionally, it showed synergy with Gemcitabine, the current first line treatment for 
pancreatic cancer (Lin, L. et. al. 2010). 
Cucurbitacin, unlike LLL12 and other Stat3 small molecule inhibitors, functions by 
targeting the JAK family of kinases.  Inhibition of these proteins blocks Stat3 activation 
at the level of the receptor complex (Jing, N. et. al. 2005).  Zhang, M. et. al. examined 
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the effect of Cucurbitacin B in pancreatic cancer.  This group found that in addition to 
decreasing Stat3 activation, this compound inhibited pancreatic cancer cell growth, 
induced apoptosis, increased p21 levels, and decreased Stat3 targets Bcl-2 and 
survivin (Zhang, M. et. al. 2010). 
 
C. Other Genetic Alterations 
As mentioned earlier, the aggressive nature of this cancer is due to the vast 
number of molecular events that occur in its development.  In addition to the major 
genetic changes seen, there are many other alterations that occur during the 
development of this cancer.  Examples of these include overexpression of the HER-
2/NEU/ERBB2 gene, mutation of the BRCA2 gene and upregulation of the proteins 
Cyclin D1 and COX-2.   
Overexpression of the HER-2/NEU gene is something that sometimes occurs as 
an early event in the development of PDAC.  Reports vary as to what percentage of 
pancreatic cancers exhibit overexpression and range from 7-82% (14).  Overexpression 
and therefore activation of this oncogene leads to constant proliferative signals through 
a multitude of pathways. 
Another late event in PDAC development is mutation of the BRCA2 gene.  
BRCA2 is involved in DNA damage repair in cells, and loss of the normal function of the 
associated protein results in accumulation of DNA damage in cells.  BRCA2 is mostly 
associated with inherited pancreatic cancer cases.  Germline BRCA2 mutations 
predispose patients to pancreatic cancer, increasing their lifetime risk by 5-10% (15).  
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Despite this, there are cases of sporadic pancreatic cancer with BRCA2 mutations.  
Around 7-10% of pancreatic cancer cases are found to have a germline BRCA2 
mutation, some of which were thought to be sporadic (4). 
Cyclin D1 is another protein often overexpressed in pancreatic cancer.  Cyclin D1 
functions normally as part of the cell cycle in conjunction with cyclin-dependent kinases 
4 and 6.  Together, these proteins inactivate the retinoblastoma gene (Rb), an inhibitor 
of cell cycle progression, and encourage the cell cycle to proceed.  Overexpression of 
CyclinD1, therefore, accelerates cell cycle progression.  Nuclear overexpression is seen 
in around 33% of PanIN-2 lesions, over 50% of PanIN-3 lesions, and in between 60-
80% of invasive PDAC (4).  Importantly, cyclin D1 overexpression has been correlated 
with decreased survival in patients with pancreatic ductal adenocarcinoma (16).   
Well known for its role in inflammation, Cox-2 also can be involved in the 
development of cancer.  One study found Cox-2 to be overexpressed by 
immunohistochemistry in between 69 and 81% of pancreatic tumors (17).  It is also 
increasingly expressed as lesion progresses from a PanIN-1 lesion to a PanIN-3 lesion 
(4). 
Changes in some of genes/proteins already discussed can lead to activation of 
not only the individual protein, but of whole pathways as well.  K-ras is an example of 
this.  Interestingly, activation of some other pathways seen in pancreatic cancer 
includes a few normally involved in embryological signaling.  The Hedgehog and Notch 
signaling pathways are actively involved in embryological development of different 
organs and are usually turned off in adult tissues.  However, in pancreatic cancer, there 
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is evidence of activation of the components of these pathways, as well as some of their 
targets, like the Hes1 gene of the Notch pathway (4).  As their embryological function 
involved regulation of cell differentiation, this activation may play a role in the abnormal 
differentiation and transformation seen in invasive pancreatic cancer (18). 
As in many types of cancer, there is a large degree of genomic instability seen 
both throughout the PanIN stages and in pancreatic adenocarcinoma.  The result is 
many chromosomal abnormalities, both numerical and structural.  Loss of chromosomal 
material can lead to some of the changes discussed above, such as loss of the 
DPC4/SMAD4/MADH4 gene, which is located on frequently lost locus 18q21 (15).  It is 
important to remember that the molecular events leading to the development of 
pancreatic adenocarcinoma are not necessarily isolated events and that they often 
represent underlying overall instability in the genome. 
As mentioned previously, this genomic instability is an early event, seen in low 
grade PanIN lesions.  Evidence of this at that stage is made apparent by shortening of 
telomeres seen in over 90% of PanIN lesions (4).  It is thought that this early loss of 
telomere length initiates a state of genomic instability by leaving chromosomes 
vulnerable and sets the stage for future molecular events to occur.   
In general, changes in K-ras, p53, INK4A, and SMAD4 provide a solid base for 
the transformation of a normal pancreatic epithelial cell into an invasive pancreatic 
adenocarcinoma.  It is clear, however, that these changes do not solely contribute to 
PDAC development and that there is a vast array of molecular events that can occur in 
different combinations to produce an invasive cancer.  The additional examples 
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discussed above (only a representative sample of the vast number of possible 
molecular changes) show how different the normal functions of these proteins can be 
and illustrate how the changes that contribute to PDAC development are very much 
widespread across the genome.  Despite some of their differences of origin or function, 
they often work synergistically to encourage cancer development.   
The correct sequence of these changes plays an important role as well.  An early 
oncogenic mutation of K-ras helps to start the push of proliferative pressure on a cell.    
The loss of gatekeeper tumor suppressors later in development relieves any final hold 
on the growth of the progressing cancer.  These timed events are important and, with 
the addition of all of the other potential molecular changes, result in the development of 
an invasive cancer that is aggressive, nearly impossible to treat, and ultimately and 
unfortunately, fatal.  
IV. Apoptosis and the Bcl-2 family of proteins 
 
Apoptosis is a biological process that is integral to normal physiological functions 
and maintenance of homeostasis in an organism.  The cell’s ability to undergo 
apoptosis is a consequence of a vast array of complex cellular processes that involve 
multiple proteins.  Apoptosis can occur through two distinct, but interrelated, pathways: 
the extrinsic pathway of apoptosis or the intrinsic/mitochondrial pathway of apoptosis 
(Figure 1). The extrinsic pathway involves activation of cell surface death receptors 
(Fas, TNFR) by extracellular ligands such as FasL or TNF.  Activation of any of the 
death receptors results in cleavage and activation of caspase-8, leading to a signaling 
cascade that culminates in death of the cell.  The intrinsic pathway, which can be 
initiated by a variety of stress signals, involves permeabilization of the outer membrane 
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of the mitochondria, which leads to cytochrome c release.  Once released, cytochrome 
c binds to Apaf-1 and forms the apoptosome, which results in cleavage and activation of 
caspase-9 and, ultimately, cell death (19).  This mitochondrial pathway is controlled 
primarily by the complex interactions of the Bcl-2 family of proteins. 
Bcl-2 is the founding member of this family of proteins and was discovered in studies 
of B-cell lymphoma.  The proteins in this family share certain sequence homology via 
the presence of Bcl-2 homology (BH) domains.  There are four BH domains that exist in 
this family and each member has at least one.  The family is divided into two groups: 
one group that has pro-apoptotic effects and one group that has anti-apoptotic effects.  
The pro-apoptotic group is further divided into two subgroups: one group containing 
proteins such as Bax and Bak and a second group containing proteins including Noxa, 
PUMA, Bim, and Bid.  The latter group is often referred to as the BH3 only proteins, as 
the members of this subgroup share sequence similarity to the rest of the family only 
through their BH3 domain.  The anti-apoptotic group includes the proteins Bcl-2, Mcl-1, 
Bcl-XL, Bfl-1/A1 and Bcl-w (20).  
Apoptosis through the intrinsic pathway is imminent when mitochondrial outer 
membrane permeabilization (MOMP) occurs.  This process arises as the result of the 
formation of homo/heterodimers of the pro-apoptotic proteins Bax and Bak.  The other 
two groups of proteins in this family ultimately regulate apoptosis by either promoting or 
inhibiting this dimerization.  The Bcl-2 family of proteins does this through physical 
interactions with each other.  Two different models have been proposed to describe 
precisely how this process might occur (Figure 2).   
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The first scheme is an ‘indirect activation model’.  In this model, the anti-apoptotic 
proteins bind to Bax/Bak and block dimerization.  The BH3 only proteins exert their pro-
apoptotic actions by binding to the anti-apoptotic proteins, thereby displacing Bax and 
Bak.  Free Bax and Bak are now free to form dimers resulting in MOMP.  The second 
theory is a ‘direct activation model’ that is somewhat more complicated.  In this model, 
the BH3 only proteins are divided into sensitizer and activator proteins.  In this model, 
Bax/Bak oligomerization occurs when the activator BH3 only proteins bind to and 
activate Bax/Bak.  The goal of the anti-apoptotic proteins is to bind the activator proteins 
and prevent them from binding and activating Bax/Bak.  Accordingly, the sensitizer BH3 
only proteins bind the anti-apoptotic proteins and prevent them from interacting with the 
activator BH3 only proteins (21).  Ultimately, it is likely that these two models may both 
occur, since apoptosis regulation is all about balance.  At a given point in the life of a 
cell, the ratio of pro-apoptotic to anti-apoptotic proteins dictates whether the cell will 
survive or undergo apoptosis.  When the pro-apoptotic proteins are expressed in 
greater quantity, the balance is pushed toward apoptosis.  However, when the ratio 
favors the anti-apoptotic proteins, cell survival will be the net consequence.   
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Figure 2: Two proposed hypothetical models of the mechanism of action of 
the Bcl-2 family of proteins. The “indirect activation model” describes a scenario in 
which the binding of anti-apoptotic proteins inhibits Bax/Bak oligomerization.  
Displacement of these anti-apoptotic proteins by a BH3 only protein allows dimers to 
form and apoptosis to occur. In contrast, the “direct activation model” holds that BH3 
only proteins are divided into two classes: activators and sensitizers. The activator 
proteins bind to Bax or Bak, activating them and leading to apoptosis. The anti-
apoptotic proteins function in this model by binding to these activator and sensitizing 
proteins and sequestering them. The BH3 only sensitizers bind to anti-apoptotic 
proteins in an attempt to displace the activator BH3 proteins. When enough activator 
BH3 proteins are free, they are able to activate Bax/Bak and induce apoptosis. 
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V. Mcl-1 (myeloid cell leukemia-1) 
 
Mcl-1 was the second member of the Bcl-2 family discovered.  Kozopas et al. (22) 
were investigating the human myeloid leukemia cell line, ML-1.  Their goal was to 
differentiate ML-1 cells into monocytes/macrophages and identify genes whose 
expression was increased during this differentiation process.  One of the early induction 
genes identified through this strategy was named Mcl-1 (myeloid cell leukemia-1) and 
was shown to have sequence similarity to the previously identified protein, Bcl-2.  Based 
on this similarity and its mode of isolation, Mcl-1 was predicted to play significant roles 
in cell differentiation and death (22).  Future studies showed that c-myc-induced 
apoptosis in CHO cells was delayed by Mcl-1 overexpression, illustrating that Mcl-1 
indeed contributed to the regulation of the cell death process (23). 
Since its discovery in 1992, studies of Mcl-1 have revealed this to be an intriguing 
protein, which performs a fundamental role in cell physiology.  Mcl-1 is an anti-apoptotic 
member of the Bcl-2 family of proteins and contains three BH domains.  This is unlike 
the other anti-apoptotic members, which contain four BH domains.  Despite this fact, it 
is the largest of the proteins, containing 350 amino acid residues (24).  Mcl-1 is also 
different than other pro-survival proteins due to its N-terminus, which is larger than that 
of other Bcl-2 family proteins and has been shown to affect Mcl-1’s function and 
localization (25).  It also contains two proline (P), gluatamic acid (E), serine (S), and 
threonine (T) (PEST) sequences (22) which may account for its relatively short half life 
(i.e., 2-3 hr), as these regions have been shown to target proteins for degradation (26). 
The structural differences seen between Mcl-1 and the other prosurvival Bcl-2 
proteins account for some of the differences seen in binding partners among these 
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proteins.  The anti-apoptotic proteins all generally function in the same way as 
described above, but the pro-apoptotic proteins with which they specifically interact 
differ.  For example, Mcl-1 binds with high affinity to the BH3-only protein Noxa, but 
does not bind to Bad.  In contrast, Bcl-2 binds well with Bad, but not as well with Noxa 
(24).   
Mcl-1 retains an alpha helical fold, similar to the other proteins, but differs in the 
exposed surface of its binding groove.  In addition to simply having different residues, 
this groove is more electropositive than the other anti-apoptotic proteins.  It is flanked on 
either side by positive electrostatic potential and contains multiple histidine residues.  
Proteins like Bcl-XL, however, have grooves that are almost completely uncharged.  
Furthermore, there are differences in the positions of some surface helices of Mcl-1, 
adding to the differences between this protein and its other family members (27).  These 
structural differences become very important in the development of inhibitors of these 
proteins.   
Mcl-1 is regulated at multiple levels, including transcriptional and translational.  
Transcriptionally, Mcl-1 expression can be induced by a variety of cytokines and 
signaling pathways, including the PI3K/AKT, Stat-3, and p38/MAPK pathways (28) 
Additionally, alternative splicing of Mcl-1 results in two protein isoforms, Mcl-1L and Mcl-
1S.  Interestingly, the Mcl-1S isoform behaves in a manner opposite to that of the normal 
protein, functioning to promote apoptosis, much like the BH3 only proteins (29).  At the 
translational level, many studies have highlighted the role of microRNAs in Mcl-1 
regulation.  Mott et al. (30) identified mir29b as targeting Mcl-1 in studies comparing 
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cholangiocarcinoma cells to normal cholangiocytes.  Additional studies have implicated 
this microRNA in Mcl-1 regulation in other cell types as well (31,32). 
Mcl-1 also contains multiple phosphorylation sites in its PEST region. Multiple 
proteins resulting in different outcomes mediate the phosphorylation of these sites.  
Thr163 can be phosphorylated by ERK leading to the increased half-life of the protein 
(33).   Conversely, GSK-3 mediated phosphorylation of Ser159 leads to increased 
ubiquitination and degradation of Mcl-1 (34).  As previously noted, Mcl-1 has a very 
short half-life.  This is due to its rapid degradation in the cell, primarily through the 
proteasome.  Proteasome-mediated degradation of Mcl-1 can occur through a variety of 
mechanisms, GSK-3-mediated phosphorylation representing the most highly 
investigated of these.  Mcl-1 Ubiquitin Ligase E3 (MULE) has been shown to 
ubiquitinate Mcl-1 on 5 different lysine residues and to be the primary mediator of 
normal Mcl-1 degradation (35).  Additionally, Mcl-1 can be targeted for degradation 
through interactions with additional proteins such as Noxa and the tumor suppressor 
SCFFBW7 (28,36). 
A. Role of Mcl-1 in Cancer 
 
Mcl-1 is highly expressed in a variety of human cancer cell lines including breast, CNS, 
colon, lung, ovarian, prostate, renal, and melanoma (Table 1)(37).  Human melanoma 
cell lines express Mcl-1, though they do not show increased expression when compared 
to normal melanocyte controls.  However, studies done in paraffin sections of benign 
nevi, primary melanoma, and metastatic melanoma showed an increase in Mcl-1 
expression that correlated with melanoma progression (38,39).   
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Mcl-1 overexpression is exploited by cancer cells to evade cell death, i.e. to 
survive, and as a mechanism for developing resistance to diverse chemotherapeutic 
agents.  The other anti-apoptotic members of the Bcl-2 family of proteins are also 
frequently overexpressed in cancers, although they will not be discussed in this review.  
Although overexpression of Mcl-1 does not result in increased cell proliferation, its 
ability to suppress apoptosis is an important contributor to the transformed state.  As 
noted earlier, apoptosis regulation is based on the balance between pro- and anti-
apoptotic proteins within cells.  The ability of a cancer cell to shift the balance toward 
survival provides it with a major advantage in protecting itself from toxic factors.  The 
clinical implications of this phenomenon may be manifested by chemoresistance.  For 
example, while chemotherapeutic agents operate through a variety of mechanisms, 
many of them are believed to act through initiation of apoptosis in a cell.  Consequently, 
protection from apoptosis via overexpression of Mcl-1 may represent a significant 
barrier to the effectiveness of chemotherapeutic agents.   
Dysregulation of Mcl-1 is an important genomic change in diverse cancers, many 
of which become dependent upon this protein for survival as well as resistance to 
chemotherapy.  Indeed, numerous reports have documented the importance of this 
protein in transformed cell survival.  Thallinger et al. (40) reported that Mcl-1 antisense 
oligonucleotides (ASO) resulted in decreased Mcl-1 expression in cell lines in vitro and 
in tumors in vivo, and that Mcl-1 ASO treatment given by paraspinal infusion of SCID 
mice with melanoma subcutaneous tumors resulted in tumor sensitization to the 
chemotherapeutic drug, DTIC, accompanied by increased levels of apoptosis in tumor 
cells (40).  In a study of head and neck cancer, twenty-six tumor samples from patients 
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with locally advanced head and neck cancer showed a 92% increase in Mcl-1 
expression (41). Transfection of Mcl-1 ASO in a head and neck squamous cell 
carcinoma cell line promoted cytotoxic synergy when combined with chemotherapeutic 
agents, Paclitaxel and Cetuximab (42).  Additionally, Mcl-1 is overexpressed in 
hepatocellular carcinoma (HCC).  Sieghart et al. (43) showed that human tumor 
specimens overexpressed Mcl-1.  They went on to show that the use of Mcl-1 ASO 
induced apoptosis in HCC cells and sensitized them to cisplatin (43).  Additionally, Mcl-
1 ASO decreased cell viability and induced apoptosis in multiple human myeloma cell 
lines as well as two primary myeloma cell lines.  This result was not seen following Bcl-2 
or Bcl-XL ASO treatment (44).  Pancreatic adenocarcinoma is another cancer that 
overexpresses Mcl-1.  Studies have shown that knockdown of Mcl-1 in a pancreatic 
cancer cell line leads to decreased cell viability and colony formation in vitro and 
decreased tumor size and weight in xenograft models.  Furthermore, loss of Mcl-1 
sensitized these resistant cells to the current first line treatment for pancreatic cancer, 
Gemcitabine (45).   
Mcl-1 has been shown to play important roles in lymphomas and leukemias as 
well.  In mantle cell lymphoma, Mcl-1 overexpression correlated with high-grade 
morphology, high levels of proliferation, and p53 overexpression (46).    Additionally, 
mice expressing a Mcl-1 transgene were shown to develop B cell lymphomas at a 
frequency of 85% over a period of 2 years (47).  In both acute and chronic leukemias, 
Mcl-1 has been demonstrated to be extremely important for cancer survival, with siRNA 
knockdown of Mcl-1 leading to apoptosis in cell lines.  Furthermore, patients who show 
resistance to Rituximab, an anti-CD20 antibody used to treat B-cell malignancies, 
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exhibit increased levels of Mcl-1.  Mcl-1 knockdown has also been demonstrated to 
sensitize cells to Rituximab treatment (48). 
VI. Strategies employed in targeting Mcl-1 
There have been numerous approaches designed to target Mcl-1.  Some of 
these schemes focus primarily on Mcl-1, but the majority of strategies target multiple 
anti-apoptotic proteins in the Bcl-2 family.  Here we review the most significant inhibitors 
developed to date.   
A. Drugs that result in Mcl-1 Downregulation 
There are multiple drugs that, despite not being designed to specifically target Mcl-1, 
display a mechanism of action that involves downregulation of Mcl-1.  Studies with 
these drugs provide continued evidence of the importance of this protein in 
maintenance and progression of the cancer phenotype.    
1. Cyclin-dependent kinase inhibitors 
Flavopiridol 
Flavopiridol is a semisynthetic flavonoid that functions as a cyclin-dependent kinase 
inhibitor by competing for the kinase active site.  It is able to inhibit the activity of 
multiple CDKs and results in G1/S and G2/S cell cycle arrest (49).  Flavopiridol also 
globally decreases transcription levels in the cell via inhibition of P-TEFb and it can also 
bind double stranded DNA (50).  However, one of the more interesting observations 
seen with Flavopiridol was its ability to downregulate Mcl-1 protein levels in B-cell 
chronic lymphocytic leukemia cells (51). Notably, significant activity was observed in 
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patients with high-risk CLL treated with a hybrid infusional flavopiridol schedule.  This 
new dosing regimen included a 30-minute loading dose prior to 4 hours of infusion given 
weekly for 4-6 weeks.  A group of 42 patients with refractory CLL were studied and of 
those 42, 45% showed a partial response.  Importantly, genetically high-risk patients 
with del(17p13.1) showed a 42% response rate and those with del(11q22.3) a 72% 
response rate (52).  
Further studies in breast cancer showed that Flavopiridol treatment 
synergistically enhanced the toxicity of the ERBB1/ERBB2 inhibitor Lapatinib in a Mcl-1-
dependent manner.  The combination of Lapatinib and Flavopiridol increased the rate of 
reduction of Mcl-1 protein compared to Flavopiridol alone.  Moreover, overexpression of 
Mcl-1 induced resistance to this combination (53). In studies involving human leukemia 
cells, Flavopiridol interacted synergistically with the HDAC inhibitor Vorinostat through a 
mechanism involving Mcl-1 down-regulation (54). 
Flavopiridol is the first cyclin-dependent kinase inhibitor to enter clinical trials.  It 
has been studied in a variety of cancer types and has shown moderate effects in some 
neoplastic diseases.  Dose-related toxicities, which include neutropenia and diarrhea, 
have limited some studies (50,55).  Interestingly, one study looking at a combination of 
Flavopiridol and Cisplatin/Carboplatin in solid tumors suggested that the lack of 
significant activity seen may be the result of the failure to achieve decreases in Mcl-1 
levels in tumors (50). Nevertheless, there is preclinical evidence of synergism between 
Flavopiridol and proteasome inhibitors associated with Mcl-1 down-regulation (56,57). 
SNS-032 
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Another cyclin-dependent kinase inhibitor, SNS-032 was originally identified in a 
screen developed to identify specific inhibitors of Cdk2.  This compound has since been 
shown to also inhibit Cdk7 and Cdk9 as well.  SNS-032, like Flavopiridol, also shows 
strong cytotoxic effects in vitro and results in decreases in anti-apoptotic proteins such 
as Mcl-1 (58).  Unfortunately, this compound exhibited disappointing results when 
evaluated in clinical trials (59).   
2. Sorafenib   
Sorafenib is a multi-kinase inhibitor that was originally developed as an inhibitor 
of B-Raf, but was subsequently shown to inhibit multiple other kinases, including 
PDGFR, FLT, Kit, and VEGFR. In human leukemia cells, pharmacologically achievable 
concentrations of sorafenib induced apoptosis through a mechanism involving Mcl-1 
down-regulation (60-62).  This has been found to be due to inhibition of translation 
resulting from sorafenib-induced ER stress (60). 
3. Deubiquitinase Inhibitors 
WP1130 
As discussed previously in this review, Mcl-1 is degraded rapidly in the cell via a 
proteasome-dependent pathway.  Blocking the proteasome can lead to increased levels 
of Mcl-1 protein.  Mcl-1 can also be rescued from degradation by deubiquitinases 
(DUBs), which are able to remove ubiquitin from ubiquitinated Mcl-1.  In a study 
investigating interactions between Mcl-1 and other proteins in the cell, Schwickart et. al. 
(63) found that one of the proteins that co-immunoprecipitates with Mcl-1 is the DUB 
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USP9X.  This group hypothesized that this interaction might lead to increased stability 
of Mcl-1 and play an important role in cancers that overexpress Mcl-1.  Indeed, they 
showed that USP9X, in addition to Mcl-1, was overexpressed in samples of ductal 
adenocarcinoma, colon adenocarcinoma, and small cell lung cancer.  Additionally, 
USP9X overexpression was found to correlate with poor prognosis in multiple myeloma.  
Knockdown of USP9X via siRNA resulted in decreased Mcl-1 protein levels, but not 
RNA levels, supporting the suggestion that USP9X knockdown results in increased Mcl-
1 degradation.  This knockdown also led to increased sensitivity of colon carcinoma and 
leukemia cells lines to ABT-737, a compound discussed later in this review, which are 
usually resistant to this agent (63).   
WP1130 is a small molecule that has multiple anti-cancer effects.  It has been 
shown to induce removal of Bcr-Abl from the cytoplasm into aggresomes, where it is not 
able to facilitate oncogenic signaling.  Additionally and most interesting for this review, it 
directly inhibits USP9X.  When used as a treatment in CML, WP1130 results in 
decreased levels of Mcl-1, compartmentalization of Bcr-Abl, and the induction of 
apoptosis (64). 
B. Antisense oligonucleotide (ASO) treatment 
Despite the fact that there are many studies looking at the effects of Mcl-1 ASO 
treatment on cancer in vitro and in animal models in vivo, there is no report of a Mcl-1 
ASO treatment being effectively translated into the clinic.  This is likely due to the issues 
that can arise with the use of ASO treatment in patients. In the human body, ASO have 
an extremely short half-life, which makes achieving sufficient blood concentrations 
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difficult.  This is partly due to the ability of DNases to degrade them.  Delivery of ASO is 
also an issue, as it is difficult to direct ASO to their specific cellular target (65). 
C. BH3 Mimetics 
The concept of BH3 mimetics has been one of the most promising translational 
strategies.  As discussed, pro-apoptotic or anti-apoptotic effects arise, ultimately, as a 
result of physical interactions between the anti-apoptotic Bcl-2 protein and the BH3 
proteins.  The anti-apoptotic proteins contain a hydrophobic binding pocket made from 
the folding of their BH1, BH2, and BH3 domains.  The BH3 domain of the BH3 only 
proteins fits into and binds this hydrophobic pocket (66).  Based on this modeling 
prediction, small molecules have been developed that mimic the BH3 domain and 
therefore are able to fit into the hydrophobic pocket of the anti-apoptotic proteins and 
block their ability to bind pro-apoptotic proteins, inhibiting their function.  Some of these 
mimetics have been developed through structural studies and others through screening 
studies.  Regardless of how these drugs were discovered, they represent a novel and 
exciting new strategy in cancer therapeutic development. 
1. ABT-737 
One of the most successful and well studied BH3 mimetics, ABT-737, was 
discovered using NMR-based screening and demonstrated strong binding affinity to the 
Bcl-2 family anti-apoptotic proteins Bcl-2, Bcl-XL, and Bcl-w.  ABT-737 does not bind to 
Mcl-1 or Bfl-1.  This difference in affinity is due to differences in the structures of these 
proteins as was described previously in this review.  Initial studies showed that ABT-737 
was effective in inducing cytotoxicity as a single agent in follicular lymphoma and small 
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cell lung carcinoma (SCLC) cell lines.  Additionally, it was found to enhance the lethality 
of paclitaxel in NSCLC (non small cell lung carcinoma) (67).  Subsequently, ABT-737 
has been widely studied in a variety of cancers.  It has been shown to induce 
cytotoxicity both in vitro and in vivo in leukemia and lymphoma, glioblastoma, multiple 
myeloma, and SCLC (68-72).  Despite many promising studies in these cancer types, 
there remain a large percentage of cancers that are resistant to ABT-737.  This 
resistance has been shown to stem from an overexpression of Mcl-1, one of the anti-
apoptotic proteins to which ABT-737 does not bind.  Even within cancers that are 
sensitive to ABT-737, specific cell lines that express higher levels of Mcl-1 display 
increased resistance to this compound (68).  Mcl-1-dependent ABT-737 resistance has 
been consistently shown in the literature and multiple studies document that 
downregulation of Mcl-1 through a variety of mechanisms is able to induce sensitivity to 
ABT-737 (73-76). Notably, the CDK inhibitor roscovitine dramatically increased ABT-
737 lethality in human leukemia cells through a mechanism involving Mcl-1 down-
regulation (77). 
Phase I/II clinical trials with ABT-263, an orally available form of ABT-737 with a 
longer half-life, are in progress in patients with SCLC, leukemia, and lymphoma.  Thus 
far, studies in chronic lymphocytic leukemia (CLL) and SCLC have shown this drug to 
be well tolerated, with some potentially manageable toxicities including back pain, 
nausea/vomiting, diarrhea, and thrombocytopenia (78).  More advanced clinical trials, 
however, have shown limited efficacy of this drug as a single agent in SCLC (79).  
2. Obatoclax (GX15)           
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Obatoclax is another example of a BH3 mimetic.  This mimetic differs from ABT-
737 in that in addition to targeting Bcl-2, Bcl-XL, and Bcl-w, it also binds to and inhibits 
Mcl-1 and Bfl-1.  Studies have shown that this compound induces cytotoxicity in a 
number of cancer types including, but not limited to, NSCLC and a variety of leukemias.  
Additionally, it has shown synergy when combined with various conventional 
chemotherapeutic agents (53,80-83).  Obatoclax also serves to again illustrate the 
importance of Mcl-1 in cancer.  Studies have shown that this compound’s cytotoxic 
effects are partially mediated through specific effects on Mcl-1.  Obatoclax can disrupt 
the constitutive Bak-Mcl-1 interaction on the outer mitochondrial membrane (84). This 
compound has advanced to clinical trials and Phase I studies in a variety of cancer 
types have shown it to be fairly well tolerated, with neurologic toxicities being the most 
common adverse event seen.  Some evidence of efficacy was seen in these studies, 
though ongoing Phase II trials will ultimately determine the effectiveness of this agent 
(85-87).   
3. Gossypol 
Gossypol is a polyphenolic aldehyde derived from cottonseed.  Original studies 
with this extract focused on its ability to function as a male contraceptive (88).  
However, it has also been shown to have potent anti-cancer activity. Gossypol functions 
as a typical BH3 mimetic and binds to and inhibits the Bcl-2 anti-apoptotic proteins Bcl-
2, Bcl-XL, and Mcl-1 (89).  Many groups have shown Gossypol to exhibit anti-
carcinogenic effects toward a wide variety of cancer types both in vitro and in vivo, 
including, but not limited to, breast, prostate, glioma, and colon cancer (88,90-93).  
LeBlanc et al. (94) also demonstrated Gossypol’s ability to inhibit growth of adrenal 
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gland carcinoma cells, medullary thyroid carcinoma cells, ovarian carcinoma cells, and 
endometrial carcinoma cells.  Compared to ABT-737, Gossypol displays toxicity against 
a much wider array of cancer types, possibly due to its ability to target Mcl-1. This 
compound has been evaluated in Phase II clinical trials as a single-agent in patients 
with advanced malignancies as well as in clinical trials that evaluated Gossypol in 
combination therapy with conventional chemotherapeutics (95-98).  
The presence of two reactive aldehyde groups on Gossypol, combined with initial 
clinical trial results that showed difficulty in achieving sufficient Gossypol blood 
concentrations, prompted groups to create Gossypol derivatives. Apogossypol was the 
first derivative designed and showed better efficacy and less toxicity than its parent 
compound (99).  To date, there have been many such derivatives created with varying 
binding affinities to the Bcl-2 anti-apoptotic proteins.   
4. Sabutoclax (BI-97C1) 
Sabutoclax (BI-97C1) is one of the newest Apogossypol derivatives developed 
by Wei et al. (89,100).  This novel compound binds to the Bcl-2 anti-apoptotic proteins 
Bcl-2, Mcl-1, Bcl-XL, and Bfl-1.  It was originally identified for its ability to bind Bcl-XL 
with low to submicromolar binding affinity.  Competitive fluorescence polarization 
assays showed that BI-97C1 inhibited Bcl-XL with an IC50 value of .31 mM.  Further 
assays showed that this compound also had displacement activity against Bcl-2 (IC50 = 
0.32 mM), Mcl-1 (IC50 = 0.20 mM), and Bfl-1 (IC50 = 0.62 mM) (100).   
Sabutoclax induced apoptosis in the large B-cell lymphoma cell line, BP3, which 
expresses high levels of Mcl-1 and Bfl-1 and is resistant to ABT-737.  Furthermore, 
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while toxic to wild type mouse embryonic fibroblasts, this compound showed only slight 
toxicity against BAX/BAK double knockout MEF cells.  This provided evidence that 
Sabutoclax only has minimal off-target effects. Additionally, as Sabutoclax showed 
efficacy against a cell line that overexpressed Mcl-1, unlike some earlier compounds 
like ABT-737, it was evaluated in the context of a prostate cancer xenograft involving 
M2182 cells, which rely on Mcl-1 for survival. A dose of 3 mg/kg induced nearly 60% 
tumor inhibition, while a dose of 5 mg/kg nearly eliminated the tumors (100). 
5. BH3-M6 
This BH3 mimetic is a very new compound designed to inhibit Bcl-2, Bcl-XL, and 
Mcl-1.  It has been shown to disrupt the interactions between these proteins and the 
pro-apoptotic BH3 only proteins.  In the lung adenocarcinoma cell line, A549, this 
compound induced apoptosis through cytochrome c release from the mitochondria.  
Preliminary studies, however, showed high doses of this compound (doses of 25 and 50 
mM) were needed to induce apoptosis.  Additional studies with this compound in other 
cancer types will be useful in determining the efficacy of this new BH3 mimetic (101). 
VII. Functional Redundancy Among the Bcl-2 Family 
As discussed previously, the majority of compounds that target Mcl-1 also affect 
other members of the anti-apoptotic Bcl-2 family of proteins.  This reflects structural and 
functional redundancy in many protein members of this gene family.  While some 
cancers rely more heavily on Mcl-1 (44), others rely on alternate anti-apoptotic 
members of the family for survival and progression (100).  Accordingly, one might try to 
identify and employ therapies for a particular cancer based on such reliance. Indeed, 
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there have been compounds, such as ABT-737, that do not target all of the anti-
apoptotic Bcl-2 proteins.  This compound is most effective in cancers that rely on 
proteins targeted by ABT-737.  However, the limitations observed with ABT-737 
highlight why targeting of specific anti-apoptotic proteins alone may not promote optimal 
therapeutic outcome.   
In addition to a lack of efficacy against cancers reliant on Mcl-1 and Bfl-1, 
multiple studies have now shown that, over time, cells sensitive to ABT-737 begin to 
develop resistance to the drug by upregulating the anti-apoptotic proteins that it does 
not target, i.e., Mcl-1 and Bfl-1.  Yecies et al. (102) showed that lymphoma cells 
subjected to long-term exposure of ABT-737 developed resistance via transcriptional 
upregulation of Mcl-1 and Bfl-1. They further demonstrated that decreasing Mcl-1 
protein levels via multiple mechanisms resulted in restored sensitivity to ABT-737 (102).  
Previously, a similar phenomenon was also seen in acute myeloid leukemia (AML) cells.  
This group noticed a positive correlation between Mcl-1 expression and ABT-737 
resistance (101).  These studies indicate that the Bcl-2 family of anti-apoptotic proteins 
may provide overlapping compensatory functions when one of the proteins is lost.  This 
supports strategies involving compounds that target all of the anti-apoptotic proteins, as 
this approach may help prevent the development of resistance mechanisms to BH3 
mimetics.   
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Chapter 2: Novel combinatorial therapy for pancreatic cancer:  
a BH3 mimetic and a synthetic tetracycline 
 
Introduction: 
Pancreatic ductal adenocarcinoma (PDAC) is an extremely aggressive cancer that is 
predicted to cause almost 40,000 deaths in the US this year (NCI 2014).  PDAC is fairly 
resistant to most standard therapies and results in a 5-year survival rate of about 4%(1).  
These dire statistics, combined with the fact that there have been minimal new 
therapies developed for PDAC over the last decade, highlight the need for new 
approaches to effectively treat this invariably fatal disease. 
The aggressive nature and dismal prognosis of patients with pancreatic cancer 
results partly from the plethora of molecular changes that occur during PDAC 
development, one of which is overexpression of the anti-apoptotic proteins of the Bcl-2 
family (103-106).  Cancer cells exploit this overexpression to evade cell death and as a 
mechanism promoting resistance to diverse chemotherapeutic agents.  Apoptosis 
reflects a balance between pro- and anti-apoptotic proteins within cells.  The ability of a 
cancer cell to shift the balance toward survival promotes resistance to toxic factors 
(107). 
Consequently, the anti-apoptotic Bcl-2 proteins have emerged as a novel 
therapeutic target.  While multiple strategies have attempted to target these molecules, 
BH3 mimetics have shown significant promise.  Pro-apoptotic or anti-apoptotic effects in 
cells arise, ultimately, as a consequence of physical interactions between anti- and pro-
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apoptotic Bcl-2 proteins (66,72).  Based on modeling predictions of these interactions, 
small molecules have been developed that mimic the BH3 domain of pro-apoptotic 
proteins and bind to the anti-apoptotic proteins, thereby impeding their ability to inhibit 
apoptosis.  These drugs represent a novel and exciting new strategy in cancer 
therapeutic development (107). 
Sabutoclax (BI-97C1) is a novel Apogossypol derivative BH3 mimetic developed 
by Wei et al. (89,99,100,108).  This compound binds to the Bcl-2 anti-apoptotic proteins 
Bcl-2, Mcl-1, Bcl-XL, and Bfl-1.  It was originally identified based on its ability to bind Bcl-
XL with low to submicromolar binding affinity (100).  We have previously shown that 
Sabutoclax shows efficacy against prostate and colorectal cancers, two cancers that 
also overexpress anti-apoptotic Bcl-2 proteins (109,110).   
Minocycline is a synthetic tetracycline antibiotic that displays marginal activity 
against multiple cancers (111-115).  However, less than stellar outcomes have 
diminished enthusiasm for using these drugs in cancer research. The marginal single 
agent effects of Minocycline against cancer may be due to the fact that it also impedes 
cell death in the face of toxicity or injury by inhibiting mitochondrial apoptosis and 
upregulation of Bcl-2 (116-118).  In an attempt to develop a unique therapeutic strategy 
for PDAC, we hypothesized that Sabutoclax and Minocycline might show therapeutic 
efficacy against this disease when used in combination because of both the reliance of 
PDAC on the Bcl-2 proteins for survival as well as the theoretical ability of Sabutoclax to 
counteract the anti-apoptotic effects of Minocycline, thereby uncovering the true 
therapeutic potential of this previously overlooked drug.   
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Materials and Methods 
Human Cell Lines 
 
MIA PaCa-2, PANC-1, BxPC-3, AsPC-1, and HPNE cells were all obtained from the 
American Type Culture Collection (ATCC).  LT2 cells were purchased from Millipore.  
MIA PaCa-2 and PANC-1 were maintained in DMEM plus 10% FBS.  BxPC-3 and 
AsPC-1 cells were maintained in RPMI plus 10% FBS.  HPNE and LT2 cells were 
maintained with media according to distributor’s instructions.  Cell lines were expanded 
and cryopreserved at early passages and new vials were thawed out and used for 
experiments approximately every 3 months.   
Creation of KPC Mouse Cell Lines 
Cell lines were derived from the ascites of tumor bearing KPC mice.  At the time of 
necropsy, ascitic fluid was collected from the mice and centrifuged to pellet tumor cells.  
The pellet was repeatedly washed in PBS and centrifuged before being resuspended in 
RPMI supplemented with 4% FBS and placed in culture.  This media was used to 
maintain these cell lines.   
Drugs and Drug Administration 
For all in vitro studies, Sabutoclax (produced by Dr. Maurizio Pellecchia) was diluted in 
DMSO and Minocycline (Sigma) in PBS.  For combination treatments, Sabutoclax and 
Minocycline were administered to cells simultaneously.  zVAD-FMK (20 µM, Promega) 
was incubated with cells for 1 hour prior to treatment with Sabutoclax and Minocycline.   
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Caspase 8 specific inhibitor, z-IETD-FMK (20 µM, BD Pharmingen) was also incubated 
with cells for 1 hour before treatment with Sabutoclax and Minocycline. 
Proliferation Studies 
5 x 103 cells were plated in 96-well plates and treated with Sabutoclax and/or 
Minocycline for 72 hours. Proliferation was assessed by MTT assay as previously 
described (119).  All data were normalized to the control.   
Cell Death Assays 
For Trypan Blue exclusion assays, 5 x 105 cells were plated in 6-cm dishes, treated as 
indicated for 48 hours, and then assayed as previously described (120). 
LDH Cytotoxicity Assays 
5 x 105 cells were plated in 6-cm dishes and treated as described.  After 48 hours, 
media was collected from each dish and assayed according to the manufacturer’s 
instructions (Cytotoxicity Detection Kit (LDH), Roche).  
Cell Cycle Studies 
1 x 106 cells were plated in 10-cm dishes and cultured in normal media with 0.5% serum 
for 48 hours.  Cells for the zero hour time point were collected and fixed at this point. 
Remaining plates were kept in either normal media or 750 nM Sabutoclax for indicated 
time points.  Once all cells were collected and fixed, they were incubated with propidium 
iodide and FACS was used for cell cycle analysis.  Cell cycle studies were done as 
previously described (121).   
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Colony Forming Assay 
MIA PaCa-2 cells were treated with Sabutoclax (500 nM), Minocycline (50 µM), or a 
combination of both for 24 hours.  Cells were then trypsinized and 1,000 cells were 
plated into 6-cm plates in triplicate.  Cells were allowed to grow and form colonies in 
normal media for approximately 14 days.  Plates were then fixed and stained with 
Giemsa. 
Western Blotting 
5 x 105 cells were plated in 6-cm dishes and treated as described. After 48 hours, whole 
cell lysates were prepared and western blotting analysis was carried out as previously 
described (120). Primary antibodies used for these studies are PARP (1:1,000), Stat3 
(1:1,000), pStat3 (1:750), Mcl-1 (1:1,000), Survivin (1:750), p21 (1:750), p27 (1:1,000), 
Cyclin D1(1:500), Caspase 2 (1:1,000), Caspase 3 (1:1,000), Caspase 6 (1:1,000), 
Caspase 7 (1:1,000), Caspase 8 (1:1,000), Caspase 10 (1:1,000), Caspase 12 
(1:1,000), AIF (1:1,000), pRB (1:750) (Cell Signaling), EF1- (1:1,000, Millipore), and 
Actin (1:5,000, Sigma).  Densitometric analysis was done using ImageJ software 
(National Institutes of Health).  
Constructs and Transfection 
Stat3Y705F Clones: MIA PaCa-2 or PANC-1 cells were transfected with a plasmid 
expressing a mutated form of Stat3 (pRc.CMV.Stat3Y705F, Addgene).  Clones were 
selected with Neomycin for approximately 2 weeks and then picked and grown up 
individually.  Whole cell lysates were made and samples were used for western blotting 
to characterize clones.  Luciferase Clones: MIA PaCa-2 or PANC-1 cells were 
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transfected with pGL3.CMV.luc (Promega).  Transfections used Lipofectamine 2000 
(Invitrogen, Carlsbad, CA) according to the manufacturer's protocol.   
Immunohistochemistry 
Tumors were fixed in formalin, embedded in paraffin, and sectioned for staining.  
Staining was done as previously described (122) with anti-p-Stat3 (1:100, Abcam), anti-
PCNA (1:100, Abcam), and anti-Mcl-1 (1:100, Abcam) per the manufacturer’s 
instructions. 
Combination Index Calculation 
Combination index (CI) values were determined for the combination of Sabutoclax and 
Minocycline in MIA PaCa-2 cells.  Values were calculated using CompuSyn software 
(ComboSyn, Inc.) according to the Chou-Talalay method.   
In vivo studies 
Subcutaneous Xenograft Studies 
5 x 106 MIA PaCa-2 and 3.5 x 106 PANC-1 cells were used to establish bilateral 
subcutaneous tumors on the flanks of 8-10 week old male athymic nude mice.  Studies 
were done as previously described (109).  Treatment began when tumors reached 
~100-mm3.  Sabutoclax was given at a dose of 1 mg/kg for both studies and was 
dissolved in a 10:10:80 solution of 100% ethanol:Cremophor:PBS.  Minocycline was 
given at a dose of 20 mg/kg and dissolved in PBS.  Both drugs were given via IP 
injection 3 times per week.  n = 5 mice/group 
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Quasi-Orthotopic Xenograft Studies 
Low Tumor Burden 
In this model, we injected 1 x 106 MIA PaCa-2-luc cells IP into 8-10 week old male 
athymic nude mice.  We allowed 1 week for tumor cells to attach and grow and then 
began treatment with PBS, 1 mg/kg Sabutoclax, 20 mg/kg Minocycline, or both 
Sabutoclax and Minocycline.  Sabutoclax and Minocycline were given via IP injection 
3x/week.  Mice were imaged by BLI at 3 weeks after treatment was initiated and then 
sacrificed at 4 weeks.  At time of sacrifice, mice were imaged pre-necropsy.  After 
necropsy, organs from a few mice/group were imaged to determine tumor specificity.  n 
= 7 mice/group 
High Tumor Burden 
5 x 106 MIA PaCa-2-luc cells were injected IP into 8-10 week old male athymic nude 
mice.  We allowed 1 week for tumor cells to attach and grow and then began treatment 
with PBS, 1 mg/kg Sabutoclax, 20 mg/kg Minocycline, or both Sabutoclax and 
Minocycline.  Sabutoclax and Minocycline were given via IP injection 3x/week.  Mice 
were sacrificed at 4 weeks.  The pancreas from each mouse was removed and weighed 
during necropsy. n = 10 mice/group 
BLI of Mice 
During imaging, mice were placed in the imaging chamber and maintained with 2% 
isoflurane gas anesthesia at a flow rate of approximately 0.5-1 L/min per mouse. 
Anesthetized mice were injected IP with 150mg/kg body weight D-Luciferin (Xenogen 
Corporation, Alameda, CA). After approximately 10 min, mice were imaged using a 
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charge-coupled-device (CCD) camera coupled to the Xenogen in vivo imaging (IVIS) 
imaging system (Caliper Life Sciences, Inc., Hopkinton, MA). The positive signal from 
background-subtracted images was analyzed by Living Image software for integrated 
density.  
Syngeneic Mouse Study 
KPC (Pdx-1-Cre/K-rasLSL-G12D/p53flox/wt) mouse cell line 48 was injected subcutaneously 
into both flanks of non-tumorigenic KPC mice (Pdx-1-Cre negative/K-rasLSL-
G12D/p53flox/wt).  Tumors were inoculated 1 week prior to initiation of treatment.  Mice 
were treated with PBS, 1.5 mg/kg Sabutoclax, 10 mg/kg Minocycline, or both 
Sabutoclax and Minocycline.  Sabutoclax was dissolved in a 10:10:80 solution of 100% 
ethanol:Cremophor:PBS.  Minocycline was dissolved in PBS.  Mice were treated with 
Sabutoclax, Minocycline, or both drugs every 2-3 days via IP injection for a total of 6 
injections.  Tumors were measured with calipers to obtain tumor volumes. n = 5 
mice/group 
Survival Study 
KPC mice (Pdx-1-Cre/K-rasLSL-G12D/p53flox/flox) were started on a Sabutoclax and 
Minocycline treatment regimen at 1 month of age.  Mice were treated with a 
combination of Sabutoclax (1.5 mg/kg) and Minocycline (10 mg/kg) via IP injection 3 
times per week.  Mice were kept on this treatment until reaching a moribund status.  At 
this point, mice were sacrificed and necropsied.  Tumor sections were obtained from 
these mice and subjected to immunohistochemistry.  n = 12 mice (control group); n = 10 
mice (Sabutoclax + Minocycline group).   
 41 
Statistical Analysis 
The data presented are the mean + S.D. of the values from three independent 
experiments.  For in vivo studies, data shown are the mean + 95% confidence interval. 
Significance was determined using the Student’s t-test.  p<0.05 was considered 
statistically significant.   
 
Results: 
Sabutoclax inhibits cell growth and induces apoptosis in PDAC  
Multiple PDAC cell lines, one immortalized pancreatic fibroblast cell line (LT2), and one 
immortalized pancreatic epithelial cell line (HPNE) were treated with increasing doses of 
Sabutoclax and assessed for effects on proliferation.  The normal cell lines displayed 
little change in cell growth (Fig. 3A-B), while all of the cancer cell lines were growth 
inhibited.  Interestingly, the sensitivity of the cancer cell lines varied, with some being 
very sensitive to Sabutoclax (MIA PaCa-2) and others more resistant (AsPC-1) (Fig. 
3A). The ability of Sabutoclax to induce cell death and apoptosis was also evaluated 
through Trypan Blue assays and detection of the cleavage of PARP, a protein cleaved 
by caspases during apoptosis (Fig. 4A-B).  Again, MIA PaCa-2 was most sensitive to 
Sabutoclax.  However, despite not showing a potent cell death phenotype, cells like 
AsPC-1 still showed profound growth inhibition following Sabutoclax treatment at higher 
doses.  Furthermore, Sabutoclax displayed greater growth inhibitory effects than the 
BH3 mimetic ABT-737 (Fig. 5A-B). 
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Figure 3: Sabutoclax inhibits cell growth and induces apoptosis in pancreatic 
cancer cells. (A) Sabutoclax dose response curves via MTT proliferation assays in 
pancreatic fibroblast cell line, LT2, and pancreatic cancer cell lines PANC-1, AsPC-1, 
MIA PaCa-2, and BxPC-3. Experiments done in triplicate and independently repeated 
three times. (B) Sabutoclax dose response curve via MTT proliferation assay in 
pancreatic epithelial-derived cell line, HPNE.  Experiments done in triplicate and 
independently repeated three times. 
A 
B 
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Figure 4: Sabutoclax inhibits cell growth and induces apoptosis in pancreatic 
cancer cells. (A) Western blotting for PARP and EF1- (loading control). Data 
representative of three independent experiments. (B) Trypan Blue assays in AsPC-1, 
PANC-1, and MIA PaCa-2.  **p<0.001 as compared to UT sample.  Experiments done 
in triplicate and independently repeated three times.  
A 
B 
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Figure 5: Sabutoclax has greater efficacy than ABT-737.  (A) MTT proliferation 
assays 72 hours post treatment.  (B) MTT proliferation assay comparing ABT-737 to 
Sabutoclax. *p < 0.001. Experiments done in triplicate and independently repeated three 
times.  
 
A 
B 
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Sabutoclax induces G1-S phase arrest  
Sabutoclax induces cell death in MIA PaCa-2 cells, without promoting potent cell 
death in either AsPC-1 or PANC-1.  Despite this, there is still a dramatic reduction in cell 
growth after drug treatment in these cell lines.  To interrogate the mechanism of growth 
suppression in these cell lines, we performed cell cycle analysis via FACS analysis (Fig. 
6-7).  Sabutoclax increased the percentage of MIA PaCa-2 subG1 phase cells, which 
have a DNA content less than 2n and are indicative of dead cells, after 24 and 48 hours, 
without affecting cell cycle, which is consistent with our previous data (Fig. 6A,D).  In 
PANC-1 and AsPC-1 cells, however, potent G1-S phase cell cycle arrest was evident 
(Fig. 6B-C).  These experiments only evaluated cells up to 48 hours post-treatment.  A 
second set of experiments also included 72 and 96 hour time points (Fig. 8-9) to 
determine if longer drug incubations promoted cell cycle arrest or resulted in a switch to 
apoptosis.  In AsPC-1, the G1-S phase arrest was sustained throughout all time points 
evaluated (Fig. 8B).  However, at 72 and 96 hours, PANC-1 showed an increase in the 
subG1 population of cells, indicating that there is an initial cell cycle arrest in these cells 
that later switches to apoptosis (Fig. 8A,C). These results emphasize the complexity of 
responses observed in PDAC to a single agent, such as Sabutoclax.  
Evaluation of cell cycle protein markers (Fig. 8D) confirmed decreased Cyclin D1 
and increased p27 expression in AsPC-1 and PANC-1 cells.  Additionally, there was a 
dramatic decrease in levels of phosphorylated Rb (Ser780).  This corresponded with the 
observed G1-S phase arrest.  Interestingly, while levels of p21 in AsPC-1 cells 
increased, p21 levels decreased in PANC-1 cells.  This difference may account for the 
switch from growth arrest to apoptosis in these cells (123,124). 
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Figure 6: Sabutoclax causes a G1-S phase cell cycle arrest.  (A-C) Cell cycle 
analysis. (D) Percentage of cells analyzed in the subG1 phase, indicating cell death. 
Data representative of three independent experiments. 
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Figure 7: Sabutoclax causes a G1-S phase cell cycle arrest. (A-C) FACS analysis 
data of graphs presented in Figure 6. Data representative of three independent 
experiments. 
 
 
C 
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Figure 8. Sabutoclax causes a G1-S phase cell cycle arrest.  (A-B) Cell cycle 
analysis. (C) Percentage of cells analyzed in the subG1 phase, indicating cell death. (D) 
Western blotting of whole cell lysates for Cyclin D1, Cyclin E, p27, p21, and phospho-
Rb.  EF1- was used as a loading control. Data representative of three independent 
experiments. 
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Figure 9: Sabutoclax causes a G1-S phase cell cycle arrest. (A-B) FACS analysis 
data of graphs presented in Figure 8. Data representative of three independent 
experiments. 
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Sabutoclax synergizes with synthetic tetracycline, Minocycline, in PDAC 
It is now almost axiomatic that to successfully combat cancer multiple targeting 
strategies used in combination will be necessary. Cancer cells develop resistance to 
initially effective treatments and acquire avoidance mechanisms preventing toxicity. 
Accordingly, combinatorial approaches attacking multiple pathways in a cancer cell can 
increase drug efficacy, reduce toxicity, and increase the time to resistance.  Based on 
this concept, we sought to identify an agent that would promote synergy when 
combined with Sabutoclax.  Minocycline, a commonly used antibiotic, can negatively 
impact cancer growth and survival (111-115).  Despite this, it paradoxically also protects 
cells in the face of an insult through inhibition of mitochondrial apoptosis and 
upregulation of Bcl-2 (116-118).  For these reasons, we hypothesized that these drugs 
might work well in combination, given their cancer-selective toxicities as single agents 
and the potential of Sabutoclax to counteract the pro-survival effects of Minocycline.   
Minocycline is fairly nontoxic to several PDAC cells (MIA PaCa-2 and PANC-1), 
but is inhibitory in others (AsPC-1 and BxPC-3) (Fig. 10).  In resistant cells, the 
combination of Sabutoclax and Minocycline is very toxic and significantly reduces cell 
proliferation and overall cell number, and induces cell death to a much greater extent 
than either agent alone in MIA PaCa-2 (Fig. 11) and PANC-1 cells (Fig. 15-16). 
Combination index values also demonstrate synergy between these two compounds 
(Fig. 13).  It also promotes increased apoptosis and reduced colony formation in PDAC 
cells.  Importantly, this synergistic effect is not evident in the non-cancerous cell line, 
HPNE (Fig. 12).  
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Figure 10: Pancreatic cancer cells exhibit varying levels of sensitivity to 
Minocycline. MTT proliferation assay in MIA PaCa-2 and PANC-1 cells (A) and AsPC-
1 and BxPC-3 cells (B) 72 hours post treatment.  Experiments done in triplicate and 
independently repeated three times. 
 
A 
B 
 53 
 
 
Figure 11: The combination of Sabutoclax and Minocycline produce synergistic 
cytotoxic effects. (A) MTT proliferation assay in MIA PaCa-2 cells 72 hours post 
treatment.  Experiments done in triplicate and independently repeated three times. (B) 
Trypan blue assays evaluating cell death and cell numbers in MIA PaCa-2 cells 48 
hours post treatment.  **p<0.0001.  Experiments done in triplicate and independently 
repeated three times.  (C) Western blotting of whole cell lysates for PARP expression in 
MIA PaCa-2 cells 48 hours post treatment.  Actin was used as a loading control.  Data 
representative of three independent experiments. (D) Colony forming assay in MIA 
PaCa-2 cells. Experiments done in triplicate and independently repeated three times.  
B 
C D 
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Figure 12: The combination of Sabutoclax and Minocycline produce synergistic 
cytotoxic effects. (A) MTT proliferation assays in HPNE cells 72 hours post treatment. 
Experiments done in triplicate and independently repeated three times. (B) LDH 
cytotoxicity assay in pancreatic epithelial cell line, HPNE. Experiments done in triplicate 
and independently repeated three times. (C) Western blotting for PARP using whole cell 
lysates from HPNE cells 48 hours post treatment.  Data representative of three 
independent experiments. 
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Figure 13: Sabutoclax and Minocycline show synergy.  Combination index (CI) 
values for the combination of Sabutoclax and Minocycline in MIA PaCa-2 cells.  
 
 
 
 
We next sought to define the mechanism underlying this synergy.   The 
combination of subtoxic doses of Sabutoclax and Minocycline induced potent cell death 
that was partially abrogated by pretreatment with zVAD, indicating that this toxic effect 
is, in part, caspase-mediated.  This rescue phenotype is evident in the morphology of 
treated cells (Fig. 14A, 16) and through reductions in LDH activity, indicating lower 
levels of cell death (Fig.14B, 15B).  Furthermore, PARP cleavage was reduced in cells 
pretreated with zVAD (Fig. 14C, 15A).  When specific caspases were evaluated, the 
combination treatment showed caspase-3 cleavage and loss of full-length caspase-8.  
In zVAD-treated samples, caspase-3 cleavage was not seen at all and levels of full-
length caspase-8 were partially restored.    
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Figure 14: The cytotoxicity induced by Sabutoclax and Minocycline is caspase-
dependent and dependent upon loss of Stat3 activation. (A) Phase contrast images 
showing MIA PaCa-2 cells 48 hours post Sabutoclax and/or Minocycline treatment. 
Experiments done in triplicate and independently repeated three times. (B) Media from 
A 
B C 
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plates photographed in panel A was collected and used for LDH activity assays. 
*p<0.005 as compared to single drug treated samples. **p=0.006 as compared to 50 µM 
Minocycline + Sabutoclax-treated samples. Experiments done in triplicate and 
independently repeated three times. (C) Western blotting of whole cell lysates for 
expression of PARP, caspase-3, and caspase-8.  Actin was used as a loading control. 
Data representative of three independent experiments.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15: Sabutoclax and Minocycline induce cytotoxicity in PANC-1 cells that is 
reversed with zVAD. (A) Western blotting of whole cell lysates for expression of PARP 
B 
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48 hours post treatment.  Actin was used as a loading control.  Cells treated with zVAD 
were incubated with the inhibitor for 1 hour prior to combination treatment.  Data 
representative of three independent experiments. (B) Media from plates used for 
western blots in panel A was used for LDH activity assays. **p=0.01.   
 
 
 
 
A 
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Figure 16: Sabutoclax and Minocycline induce cytotoxicity in PANC-1 cells that is 
reversed with zVAD. (A) Phase contrast images showing PANC-1 cells 48 hours after 
treatment.  Data representative of three independent experiments. 
 
 
 
The cytotoxic effect of Sabutoclax and Minocycline is Stat3-dependent 
Stat3 activation is clinically relevant for PDAC as constitutive activation of Stat3 
has been reported in 30-100% of human tumor specimens, and is crucial for PDAC 
initiation, progression, and maintenance (125). Sabutoclax treatment resulted in a 
potent loss of Stat3 phosphorylation (Tyr 705), as well as a loss of downstream Stat3 
targets, such as survivin (Fig. 17A).  Minocycline alone induced similar changes (Fig. 
17B).  Subtoxic doses of each drug lowered Stat3 activation, but the combination of 
both drugs almost completely eliminated pStat3 expression (Fig. 17C).  To determine 
whether this would affect the cytotoxicity of the combination, we created MIA PaCa-2 
clones stably expressing an activated Stat3 mutant, Stat3 Y705F, e.g. C 13 (Fig. 18A).  
As compared to the parental cell line, C 13 showed enhanced resistance to combination 
treatment (Fig. 18B).  A similar elevated resistance was observed in other Stat3 Y705F 
overexpressing MIA PaCa-2 clones (data not shown). Because pretreatment with zVAD 
partially rescued cells from Sabutoclax and Minocycline-induced cell death, we 
evaluated expression of a variety of caspases to determine their potential involvement 
not only in death induced by the combination, but which ones might be affected in C 13 
cells (Figure 18C).  In parental MIA PaCa-2 cells, caspases 3, 7, and 8 were cleaved.  
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Loss of full-length caspases 2 and 6 was evident, whereas AIF, caspase 12, and 
caspase 10 (caspase 10 data not shown) were not significantly altered.  In C 13 cells, 
however, we did not see any significant changes in any caspase examined, supporting 
the observation that loss of Stat3 activation is necessary for caspase-dependent cell 
death by Sabutoclax and Minocycline.  We also created stable cell lines overexpressing 
Stat3 Y705F in PANC-1 cells.  Similar to what we observed in MIA PaCa-2 cells, 
constitutive Stat3 activation in these clones protected them from cytotoxicity induced by 
the combination of Sabutoclax and Minocycline (Fig. 19).   
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Figure 17: The cytotoxicity induced by Sabutoclax and Minocycline is caspase-
dependent and results in loss of Stat3 activation. (A-B) Western blotting of whole 
cell lysates for pStat3 Tyr705, Stat3, Survivin, Actin (loading control) and EF1- (loading 
A B 
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control) 48 hours post treatment. Data representative of three independent experiments. 
(C) Western blotting of whole cell lysates for pStat3 Tyr705 48 hours post treatment.  
Actin was used as a loading control.  Cells were incubated with zVAD for 1 hour prior to 
Sabutoclax and Minocycline treatment. Data representative of three independent 
experiments.  
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Figure 18: The cytotoxicity induced by Sabutoclax and Minocycline is dependent 
upon loss of Stat3 activation. (A) Western blotting of whole cell lysates from MIA-
PaCa-2-Stat3Y705F stable clones for pStat3 Tyr705.  Actin was used as a loading 
control.  Graph below blot shows quantification. Data representative of three 
independent experiments. (B) Western blotting of whole cell lysates for PARP in 
parental MIA Paca-2 and Stat3Y705F stable clone 13.  Actin was used as a loading 
control.  Sab = 500 nM Sabutoclax, Mino = 50 µM Minocycline. Data representative of 
three independent experiments. (C) Western blotting of whole cell lysates 48 post 
treatment for PARP, AIF, Caspase-7, Caspase-8, Caspase-12, Caspase-2, Caspase-6, 
and Caspase-3. Actin was used as a loading control. Data representative of three 
independent experiments.  
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Figure 19: The cytotoxicity induced by Sabutoclax and Minocycline is dependent 
upon loss of Stat3 activation. (A) Western blotting of whole cell lysates from PANC-1-
Stat3Y705F stable clones for pStat3 Tyr705.  Actin was used as a loading control. (B) 
Western blotting of whole cell lysates for PARP in parental PANC-1 cells and 
Stat3Y705F stables clones 8 and 11.  Actin was used as a loading control. Data 
representative of three independent experiments. 
 
 
 
Sabutoclax and Minocycline induce cytotoxicity through the intrinsic pathway of 
apoptosis 
B 
A 
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Caspase-8 activation is an integral part of the extrinsic pathway of apoptosis.  
However, it can also be activated independent of this pathway by other caspases (126).  
To determine if caspase-8 involvement was due to extrinsic pathway activation or 
downstream intrinsic pathway activation, we used Z-IETD-FMK to specifically inhibit 
caspase 8 before drug treatment. Unlike the pan caspase inhibitor, zVAD, pretreatment 
with Z-IETD-FMK did not protect cells from Sabutoclax and Minocycline-induced cell 
death (Fig. 20).  This indicates that caspase-8 activation is dispensable for Sabutoclax 
and Minocycline-induced cell death and is most likely a secondary effect of other 
caspases.  Therefore, our data support the hypothesis that Sabutoclax and Minocycline 
induce a cytotoxic phenotype through activation of the intrinsic pathway of apoptosis.  
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Figure 20: The cytotoxicity induced by Sabutoclax and Minocycline works 
through the intrinsic pathways of apoptosis. Western blotting 48 hours post 
treatment for PARP and Actin (loading control).  Cells were incubated with zVAD or z-
IETD-FMK for 1 hour prior to treatment with Sabutoclax and Minocycline.  Data 
representative of three independent experiments. 
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Sabutoclax alone reduces tumor growth in a xenograft model of pancreatic 
cancer and this effect is enhanced with the addition of Minocycline 
Luciferase-expressing MIA PaCa-2 cells, displaying a similar phenotype as 
parental cells (Fig. 21A), were established as subcutaneous xenografts in athymic nude 
mice, which were then treated with Sabutoclax (1 mg/kg), Minocycline (20 mg/kg), or 
both agents.  Both drugs were given via IP injection 3x/week. Minocycline treatment 
alone showed minimal effects, while Sabutoclax alone showed greater reductions in 
tumor weight and growth (Fig. 21B-C).  Despite this, animals treated with a combination 
of Sabutoclax and Minocycline showed a synergistic reduction in tumor growth, with a 
significantly smaller tumor growth rate, even as compared to Sabutoclax alone (Fig. 
21C).  This was confirmed with bioluminescence imaging (BLI) (Fig. 21D).  A similar 
experiment was conducted using PANC-1-luc cells resulting in the same trend, with the 
combination group showing significant inhibition of tumor growth (Fig. 23).  
Immunohistochemistry of tumor sections  (Fig. 22) demonstrated higher intensity 
proliferation marker PCNA staining in control, Sabutoclax, and Minocycline-treated 
groups as compared to the combination-treated group.  Furthermore, combination-
treated tumors showed significantly less phosphorylated Stat3 expression, consistent 
with in vitro observations. 
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Figure 21: Sabutoclax reduces tumor growth in a subcutaneous xenograft model 
and is enhanced by the addition of Minocycline. (A) MTT proliferation assay of MIA 
PaCa-2 cells stably expressing luciferase after treatment with Sabutoclax and/or 
Minocycline.  ***p<0.0001. Experiments done in triplicate and independently repeated 
three times. (B) Tumor weight as normalized to the control animals at the end of the 
experiment. (C) Tumor growth kinetics of MIA PaCa-2-luc cell subcutaneous tumors on 
the flanks of athymic mice. *p<0.04 as compared to all other groups. (D) 
Bioluminesence imaging (BLI) of tumors and image quantification.  Exposure time = 5 
seconds. n= 5 mice/group. 
A 
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Figure 22: Sabutoclax and Minocycline reduce PCNA expression and Stat3 
activation in vivo. Tumors were fixed in formalin, embedded in paraffin, and sectioned 
for staining. Representative images of immunohistochemistry (IHC) stained with p-Stat3 
Y705 and PCNA.  Arrows in PCNA images show margin of negatively stained tumor 
area at the periphery of each tumor.  Data representative of three independent 
experiments. 
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Figure 23: Sabutoclax and Minocycline reduce tumor growth in a subcutaneous 
xenograft model of pancreatic cancer. (A) Tumor growth kinetics of PANC-1-luc cell 
subcutaneous tumors on the flanks of athymic mice. *p<0.04 as compared to all other 
groups. (B) Bioluminesence imaging (BLI) of tumors.  Exposure time = 8 seconds. n= 5 
mice/group 
A 
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Quasi-orthotopic xenograft mouse model 
While subcutaneous xenograft studies are useful in evaluating in vitro 
observations in an in vivo setting, flank tumors do not accurately mimic natural disease 
states.  To study the effect of our drugs in a more natural setting, we used a quasi-
orthotopic model of PDAC (127).  We found that MIA PaCa-2-luc cells, when injected 
intraperitoneally, specifically homed to the pancreas, with the majority of tumors or 
tumor nodules found in this organ.  Other locations in which we found tumors (liver, 
peritoneal lining) are common places for this cancer to metastasize and more closely 
mimic the clinical picture of this disease.   
In an initial set of experiments, we injected 1 x 106 cells i.p. and allowed 1 week 
for tumor establishment before treating mice with Sabutoclax and Minocycline, alone or 
in combination. Consistent with our previous data, Minocycline as a single agent did not 
have any effect and mice presented similarly to control animals.  Sabutoclax showed a 
potent single-agent effect, with fewer animals showing evidence of disease.  The 
combination group showed even more promise (Fig. 24C), with only 1/7 mice showing 
tumors by BLI (Fig. 24A-B).  Pancreas weight did not show significant differences, 
though the trend supported our other observations (data not shown).  
A second quasi-orthotopic study was conducted using similar drug dosing 
parameters.  Tumors, though, were initiated with the injection of 5 x 106 cells as 
opposed to 1 x 106.  In our first study, the use of fewer cells allowed testing whether 
Sabutoclax and Minocycline could prevent tumor formation.  However, the use of fewer 
cells also means that the overall tumor burden was less when therapy was initiated, 
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which prevented determining the true magnitude of the effect Sabutoclax and 
Minocycline would have in the context of a greater tumor burden, which might more 
closely imitate the clinical setting.   
As anticipated, injecting a greater number of cells resulted in a larger overall 
tumor burden in the animals.  Mice from all groups developed tumors or tumor nodules 
in the pancreas.  However, the weight of the pancreas from mice treated with both 
Sabutoclax and Minocycline was significantly less than those from animals in all 3 other 
groups and visually showed fewer gross nodules (Fig. 24D).  
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Figure 24: Sabutoclax and Minocycline reduce tumor growth in a quasi-orthotopic 
xenograft model. (A) Low Tumor Burden study: BLI images of mice post treatment.  
Exposure time = 5 seconds. (B) Image quantification of panel A.  (C) Tumor incidence in 
pancreas – measured by imaging and by gross examination of animals at necropsy. n= 
7 mice/group. (D) High Tumor Burden study: pancreas weight at necropsy.  Treatment 
groups normalized to the control. *p=0.03, **p=0.01, ***p=0.004. n= 10 mice/group 
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Sabutoclax and Minocycline in a transgenic mouse model of PDAC (KPC) 
The KPC transgenic PDAC mouse model is used frequently in PDAC research 
(128-132). This animal spontaneously develops precursor pancreatic lesions, PanINs, 
which progress and eventually develop into invasive disease. Tumors form as a result of 
activated K-ras and functional loss of p53 in the pancreas, genetic changes also seen in 
a high percentage of human tumors.  Histological analysis shows extensive local 
invasion as well as metastasis in a subset of animals (133). 
Pancreatic tumors from these mice overexpress Mcl-1 as shown by 
immunohistochemistry (Fig. 25A).  This is consistent with the disease observed in 
humans (103-106) and provides a rationale for using Sabutoclax in these animals.  
Additionally, cell lines derived from these animals show combination effects with 
Sabutoclax and Minocycline (Fig. 25B).  These cells were injected subcutaneously into 
the flanks of control KPC mice (Pdx-1-Cre-negative/K-rasLSL-G12D/p53flox/wt) and allowed 
to grow for approximately one week.  Mice were treated with Sabutoclax, Minocycline, 
or both drugs every 2-3 days via i.p. injection for a total of 6 injections.  Sabutoclax or 
Minocycline alone did not significantly affect tumor growth.  The combination of drugs, 
however, significantly inhibited tumor growth as compared to controls (Fig. 26).  
Immunohistochemistry of tumor sections demonstrated decreased staining for PCNA 
and pStat3 in combination-treated tumors (Fig. 27-28).  
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Figure 25: KPC tumors express Mcl-1 and KPC cell lines show sensitivity to 
Sabutoclax and Minocycline. Tumors from Pdx-1-Cre/K-rasLSL-G12D/p53flox/wt and Pdx-
1-Cre/K-rasLSL-G12D/p53flox/flox mice overexpress Mcl-1 and show sensitivity to Sabutoclax 
and Minocycline.  (A) IHC for Mcl-1 in sections of pancreas from control, Pdx-1-Cre/K-
rasLSL-G12D/p53flox/wt and Pdx-1-Cre/K-rasLSL-G12D/p53flox/flox mice.  (B) Western blotting of 
whole cell lysates for PARP 48 post treatment in cell lines derived from Pdx-1-Cre/K-
rasLSL-G12D/p53flox/wt mice.  Data representative of three independent experiments. 
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Figure 26: Sabutoclax and Minocycline reduce tumor growth in a syngeneic KPC 
model. Syngeneic study: Tumor growth kinetics of control Pdx-1-Cre negative/K-rasLSL-
G12D/p53flox/flox mice bearing subcutaneous Pdx-1-Cre/K-rasLSL-G12D/p53flox/wt–derived 
tumors. **p<0.01 as compared to all other groups. n= 5 mice/group. 
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Figure 27: Sabutoclax and Minocycline reduce proliferation in a syngeneic KPC 
model. IHC for PCNA. Data representative of three independent experiments.  
 
 
 
 
 
 
 
 79 
 
Figure 28: Sabutoclax and Minocycline reduce Stat3 activation in a syngeneic 
KPC model. IHC for pStat3 Y705. Data representative of three independent 
experiments.  
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Additionally, a survival study was done using KPC mice (Pdx-1-Cre/K-rasLSL-
G12D/p53flox/flox) to determine the effects of Sabutoclax and Minocycline.  Mice were 
treated with Sabutoclax (1 mg/kg), Minocycline (10 mg/kg), or a combination of both 
three times a week via i.p. injection starting at around 1 month of age and continuing 
until animals reached a moribund state.  Mice receiving combination treatment showed 
a significant survival advantage as compared to control mice (Fig. 29).  Importantly, no 
toxicity was seen from either drug in any of the animal studies conducted.   
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Figure 29: Sabutoclax and Minocycline enhance survival in the KPC transgenic 
mouse model. Kaplan-Meier survival curve for Pdx-1-Cre/K-rasLSL-G12D/p53flox/flox mice 
treated with Sabutoclax and Minocycline.  *p=0.001. n = 12 mice (control group); n = 10 
mice (Sabutoclax + Minocycline group).    
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Discussion: 
Pancreatic cancer is one of the most lethal cancers, remaining largely 
untreatable.  Moreover, advances in therapy have been minimal over the last 15 years, 
due in part to the aggressive nature of PDAC and the difficulty in developing selective 
and effective therapeutics.  We presently describe an efficacious novel drug 
combination for PDAC that uses a new BH3 mimetic and uncovers the hidden 
therapeutic potential of Minocycline as an anti-cancer agent.  
Considering overexpression of the anti-apoptotic Bcl-2 proteins in PDAC, we 
initially evaluated the efficacy of Sabutoclax, a BH3 mimetic that targets these anti-
apoptotic proteins, inhibiting their function.  Sabutoclax was effective as a single agent.  
It induced cancer-inhibitory effects in multiple genetically diverse PDAC cell lines.  
Potent apoptosis-inducing activity was evident in some PDAC cell lines and in those 
that only showed minor increases in death, we found instead a potent cell cycle arrest.  
Tumor heterogeneity is a problem manifested to some degree in all cancers, but is 
especially relevant in PDAC, contributing to the global resistance seen in this cancer to 
conventional chemotherapeutics.  A beneficial aspect of Sabutoclax is its anti-cancer 
activity in multiple PDAC cell lines, irrespective of genetic background.   
Despite the potential of Sabutoclax as a single-agent, there is a pressing need 
for combination therapy in the clinical setting.  Cancer is an adaptive disease and 
effectively combatting it requires a multifaceted approach.  Because of this, we sought 
to find a second drug that would potentially synergize with Sabutoclax to further 
promote its clinical applicability.  We focused on the antibiotic, Minocycline, which has a 
small literature base supporting a novel role for this drug in the field of cancer (111-
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115).  Despite these reports, translational cancer research using tetracyclines never 
expanded as only minor efficacy was evident with these drugs.  In addition to its 
classical role as an antibiotic, Minocycline has also been studied extensively as a 
neuroprotective agent.  Zhu, et. al. showed that this neuroprotection develops, in part, 
through the inhibition of caspase-9 and caspase-3 activation after exposure to death-
inducing stimuli due to the inhibition of cytochrome c release from mitochondria (118).  
Minocycline has also been shown to lead to increases in the expression of anti-
apoptotic Bcl-2 proteins like Bcl-2 (116,117).  We hypothesized that these properties 
might actually mask the true potential of Minocycline as a cancer therapeutic and 
contribute to the disappointing results seen in the past.  However, we hypothesized that 
these properties might make it an ideal combination partner for Sabutoclax.  Sabutoclax 
works by directly acting at the level of the mitochondria, specifically inducing apoptosis 
driven by cytochrome c release.  In combination with Sabutoclax, the block on apoptosis 
in cells treated with Minocycline may be released, thereby leading to synergistic anti-
cancer properties.   
Our study has shown that Sabutoclax plus Minocycline is exceptionally effective 
against pancreatic cancer (Fig. 30).  Subtoxic individual doses of each drug produced a 
dramatic synergistic cytotoxic effect.  Furthermore, we found that this combination 
resulted in a loss of Stat3 activation.  Reintroduction of a constitutively active Stat3 
mutant into cells rendered them resistant to the combination of Sabutoclax and 
Minocycline. This combination shows promise in vivo using multiple mouse models, 
both immune-compromised and immune-competent transgenic models of PDAC, 
showing significant anti-cancer activity without any signs of gross toxicities.   
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In summary, we describe an innovative combinatorial therapeutic approach with 
remarkable activity against pancreatic cancer cells in vitro and in vivo in three animal 
PDAC models. Considering the paucity of effective therapies for PDAC, it is clear that 
new approaches are mandatory to impact clinically on this invariably fatal cancer. The 
ability to target the Bcl-2 family for inactivation, using Sabutoclax, and combining this 
with a simple synthetic tetracycline antibiotic, such as Minocycline, opens up new areas 
of research with the potential to lead to an effective therapy for pancreatic cancer. 
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Figure 30: Overview model showing therapeutic effects of Sabutoclax and 
Minocycline in PDAC. 
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Chapter III: Gemcitabine Chemotherapy Modification for the  
Treatment of Pancreatic Cancer 
 
Introduction: 
Pancreatic cancer is an extremely deadly disease, with a 5-year survival rate of 
less than 5%.  Most tumors are either locally advanced or metastasized at the time of 
diagnosis and, intrinsically, this cancer is extremely resistant to chemotherapy and 
radiation.  Currently, first line treatment for pancreatic cancer consists of surgical 
resection, if possible, and a subsequent course of chemotherapy.  This chemotherapy 
usually consists of treatment with Gemcitabine (2).   
In 1997, Burris, et al. published a clinical study comparing Gemcitabine to 5-
Fluoruracil for the treatment of pancreatic cancer.  In this study, 126 patients were 
enrolled with 63 per treatment group.  23.8% of patients showed clinical benefit with 
Gemcitabine, as compared to only 4.8% of 5-FU-treated patients.  The median survival 
was shown to be 5.65 months for Gemcitabine and 4.41 months for 5-FU.  Finally, 18% 
of patients treated with Gemcitabine were alive at 12-month time point, while survival at 
this time point for patients treated with 5-FU was only 2% (3). This trial helped 
encourage the FDA to approve Gemcitabine for the treatment of pancreatic cancer in 
1998.  Gemcitabine is currently a standard treatment used for patients with pancreatic 
cancer.  Despite this, the drug only provides minimal benefit to patients.   
Gemcitabine’s cytotoxic effects are due to its ability to act as a pyrimidine analog.  
Gemcitabine triphosphate acts as an analog for deoxycytidine triphosphate, which 
allows it to be incorporated into DNA during replication.  After Gemcitabine is 
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incorporated, another nucleotide may be added to the chain, but inhibition of chain 
elongation subsequently occurs.  DNA damage repair is not able to remove the drug 
and, consequently, apoptosis occurs (134).    
Gemcitabine enters the cell through multiple cell membrane transporters, though 
the sodium-independent transporter, hENT1, has been shown to preferentially transport 
Gemcitabine (134).  Though there are multiple mechanisms of Gemcitabine resistance, 
one important mechanism revolves around expression of this protein.  Giovannetti, et al. 
showed that patients with tumors that express high amounts of hENT1 have a greater 
survival advantage with Gemcitabine treatment as compared to those with lower hENT1 
expression (Giovannetti, et al. 2006).  Patients with higher hENT1 expression have 
tumors that can more readily take up Gemcitabine, leading to an increased clinical 
benefit.  However, in many tumors, low expression of Gemcitabine transporters 
translates to a need for the drug to be administered frequently and at high doses, two 
things that can add significantly to drug toxicity. 
Toxicity is a major issue with many chemotherapeutic agents and, as a result, the 
creation of more targeted therapies that have a lower risk of toxicity has become an 
attractive strategy in developing cancer therapeutics.  Many conventional 
chemotherapeutic drugs work well in killing cells, but because they also target normal 
cells, often lead to high levels of toxicity.  Targeted therapies focus on attacking cancer 
cells specifically and sparing normal cells to reduce ill side effects.  One specific 
strategy of targeted therapy involves modifying currently used drugs to make them 
cancer specific.  This often involves identifying a biomarker on cancer cells that the 
modified drug can target.  One such target is the Ephrin receptor. 
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Ephrin receptors are a family of tyrosine kinase receptors involved in neuronal 
connectivity, blood vessel development, and cell-cell interactions.  EphA2 was identified 
in 1990 and is expressed in the majority of epithelial cells.  In cancer cells, EphA2 is 
highly overexpressed and encourages communication not only between individual 
cancer cells, but also between cancer cells and surrounding stromal or vascular cells.  
EphA2 overexpression also correlates with poor prognosis in patients.  Despite EphA2 
overexpression, expression of EphrinA1, its ligand, often remains normal even in a 
cancerous state.  This can lead to accumulation of unactivated EphA2 and subsequent 
oncogenic activity (135). 
Peptides have been created that, similar to the natural ligand for this receptor, 
selectively bind EphA2 and cause receptor activation and internalization.  These 
peptides are linked to commonly used chemotherapeutic drugs and act as a specific 
delivery strategy for these drugs to tumor cells.  Once the receptor is activated, the 
peptide and its attached drug are internalized into a lysosome, where the peptide is 
degraded and the drug is free to exert its toxic effects on the cell (136).  Previous 
studies have shown that Paclitaxel conjugated with these peptides shows increased 
efficacy in prostate and renal cancers (137). 
Gemcitabine, though the current first-line treatment for pancreatic cancer, does 
not offer a great therapeutic benefit to patients.  This study aims to study a modified 
version of Gemcitabine as an alternate to the traditional drug.  This modified drug, YNH-
Gemcitabine, consists of the drug with a peptide attached (YNH).  This peptide was 
designed to specifically bind to the EphrinA2 receptor, which is overexpressed on 
pancreatic cancer cells.  The result of this is that the attached Gemcitabine gets 
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internalized into the cell via EphA2, bypassing its normal mechanism of cellular entry.  
We believe that this will allow a greater amount of Gemcitabine to enter the pancreatic 
cancer cell and, ultimately, show greater efficacy in vivo as compared to traditional 
Gemcitabine alone.   
To expand these studies, we also evaluated 123B9, a newer derivative of the 
previously developed YNH family of compounds.  Though the YNH compounds showed 
good efficacy, the terminal tyrosine of YNH could be degraded by aminopeptidases in 
the blood, which limited its half-life.  123B9 contains a synthetic tyrosine that is resistant 
to aminopeptidase degradation, leading to a significantly longer half-life in blood and, 
hopefully, greater efficacy as well.  Due to the recent approval of Gemcitabine and 
Abraxane as first-line therapy for metastatic pancreatic cancer, we evaluated 123B9-
Paclitaxel and Gemcitabine.  Additional studies evaluating 123B9-Gemcitabine versus 
Gemcitabine in pancreatic cancer are currently in progress.  
Materials and Methods: 
 
Human Cell Lines 
MIA PaCa-2, PANC-1, BxPC-3, and AsPC-1 cells were all obtained from the American 
Type Culture Collection (ATCC).  LT2 cells were purchased from Millipore.  MIA PaCa-2 
and PANC-1 were maintained in DMEM plus 10% FBS.  BxPC-3 and AsPC-1 cells were 
maintained in RPMI plus 10% FBS. LT2 cells were maintained with media according to 
distributor’s instructions.  Cell lines were expanded and cryopreserved at early 
passages and new vials were thawed out and used for experiments approximately 
every 3 months.   
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Drugs and Drug Administration 
Gemcitabine, YDH-Gemcitabine, YNH-Gemcitabine, Paclitaxel, 123B9, 123B9-
Paclitaxel and 123B9-Gemcitabine were produced by Dr. Maurizio Pellecchia (Sanford-
Burnham Institute, La Jolla, CA).  For biological studies, all drugs were diluted in 10% 
Tween80, 10% DMSO, and 80% PBS.  
 
Western Blotting 
5 x 105 cells were plated in 6-cm dishes and treated as described. After 48 hours, whole 
cell lysates were prepared and western blotting analysis was carried out as previously 
described (120). Primary antibodies used for these studies were EphrinA2 (1:1,000, Cell 
Signaling) and EF1-α (1:5,000, Sigma).  
 
Subcutaneous Xenograft Studies 
5 x 106 MIA PaCa-2-luciferase cells were used to establish bilateral subcutaneous 
tumors on the flanks of 8-10 week old male athymic nude mice.  Studies were done as 
previously described (109).  Treatment began when tumors reached ~100-mm3.  All 
drugs were administered by tail vein injection twice per week for 4 weeks, a total of 8 
injections. Gemcitabine was given at a dose of 10 mg/kg and all Gemcitabine 
derivatives were given at equimolar doses to 10mg/kg Gemcitabine, also via tail vein 
injection. PTX was given at a dose of 2.5mg/kg.  All 123B9 compounds were given in 
equimolar doses to PTX.  BLI was done at the beginning and end of the study.  Tumors 
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were measured twice per week using calipers.  Tumors were fixed in formalin, 
embedded in paraffin, and sectioned for staining.   
 
Survival Study 
After their last injection, mice were kept for 1 additional week to monitor tumor growth 
and imaged at the end of this week. The mice were then kept to monitor for the effects 
of treatment on survival. Mice were kept until reaching a moribund status or until tumors 
reached a combined volume of 2000mm3, whichever came first.  They were then 
sacrificed at this time. 
 
BLI  
During imaging, mice were placed in the imaging chamber and maintained with 2% 
isoflurane gas anesthesia at a flow rate of approximately 0.5-1 L/min per mouse. 
Anesthetized mice were injected IP with 150 mg/kg body weight D-Luciferin (Xenogen 
Corporation, Alameda, CA). After approximately 10 min, mice were imaged using a 
charge-coupled-device (CCD) camera coupled to the Xenogen in vivo imaging (IVIS) 
imaging system (Caliper Life Sciences, Inc., Hopkinton, MA).  
 
Statistical Analysis 
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For in vivo studies, data shown are the mean + 95% confidence interval. Significance 
was determined using the Student’s t-test.  p<0.05 was considered statistically 
significant.   
Results: 
 
YNH-Gemcitabine shows greater efficacy in vivo compared to Gemcitabine 
 
MIA-PaCa-2-luc cells were used to create bilateral subcutaneous xenografts in 
athymic mice.  Western blot data shows that this pancreatic cancer cell line highly 
expresses EphA2 (Figure 31).  Cells were injected into each flank and then allowed to 
grow for approximately 1 week.  At this point, mice were imaged using BLI and 
treatment was subsequently initiated.  Mice were divided into 4 groups (PBS, 
Gemcitabine, YDH-Gemcitabine, YNH-Gemcitabine) with 9 mice/group.  YDH-
Gemcitabine is a scrambled control, where the peptide attached to Gemcitabine should 
not be specific for EphA2 and, therefore, should not bind to the receptor.  Animals were 
treated 2x/week via tail vein injection for 4 weeks.  A dose of 10mg/kg Gemcitabine was 
used along with equimolar doses of YDH-Gemcitabine and YNH-Gemcitabine.  At the 
end of 4 weeks, animals were again imaged and treatment was ended.   
As expected, YDH-Gemcitabine did not have significant effects on tumor growth.  
Gemcitabine had a modest effect on tumor growth, though YNH-Gemcitabine showed 
the greatest inhibition of tumor growth of all groups evaluated (Fig. 32).  This can be 
observed both through tumor measurement and by BLI (Fig. 33).  No negative side 
effects of the drugs were observed and the mouse weight remained consistent 
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throughout the study (data not shown).  3 animals per group were sacrificed at the end 
of this study and tumors were excised and fixed in formalin for further study.  
To determine whether YNH-Gemcitabine also gave a survival advantage, 
remaining mice were not sacrificed at the end of the experiment, but rather when their 
individual tumor burden approached 2000mm3.  YNH-Gemcitabine gave mice a 
significant survival advantage over other treatment groups (Fig. 34).  
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Figure 31: Pancreatic Cancer cells express EphA2. Western blotting of normal 
pancreatic fibroblasts and pancreatic cancer cells.  
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Figure 32 : YNH-Gemcitabine inhibits tumor growth in vivo to a greater extent as 
compared to Gemcitabine. Tumor volume as calculated by caliper tumor 
measurement.  *p < 0.05;** p<0.01. n=9 mice/group 
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Figure 33 : YNH-Gemcitabine inhibits tumor growth in vivo to a greater extent as 
compared to Gemcitabine. Bioluminescent tumor images at Day 34.  Exposure time = 
0.5 seconds 
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Figure 34: YNH-Gemcitabine prolongs in a xenograft model of pancreatic cancer.  
Kaplan-Meier curve showing survival in days.   *p < 0.05.  
 
 
 
 
 
 
 
 
 
* 
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123B9-Paclitaxel and Gemcitabine show combination effects in pancreatic cancer 
in vivo 
 
MIA-PaCa-2-luc cells were used to create bilateral subcutaneous xenografts in 
athymic mice.  Cells were injected bilaterally into the flanks and then allowed to grow for 
approximately 1 week.  At this point, mice were imaged using BLI and then treatment 
was initiated.  Mice were divided into 8 groups (Control, Gemcitabine, PTX, Gem+PTX, 
123B9-PTX, 123B9+PTX, 123B9-PTX+Gem, 123B9+PTX+Gem) with 5 mice/group.  
Animals were treated 2x/week via tail vein injection for 4 weeks.  A dose of 10mg/kg 
Gemcitabine, 2.5mg/kg PTX, and an equimolar dose of the 123B9 compounds were 
used.  Tumors were measured with calipers twice a week.  At the end of 4 weeks, 
animals were again imaged and treatment was stopped.  No negative side effects from 
any of the compounds used were observed and the mouse weight remained consistent 
throughout the study (data not shown).  
As expected, Gemcitabine or PTX treatment alone did not have a significant 
effect on tumor growth, but the combination of these two drugs did significantly inhibit 
tumor growth (Fig. 35).  Additionally, both 123B9-PTX and 123B9+PTX showed greater 
inhibition of tumor growth as compared to PTX (Fig. 36).  The addition of Gemcitabine 
to these groups further suppressed tumor growth.  Mice that were treated with 
123B9+PTX+Gem showed the greatest inhibition of tumor growth (Fig. 37).  Tumors in 
this group were significantly smaller as compared to 123B9+PTX, PTX, Gem, and 
Control groups.   
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Figure  35: Gemcitabine (Gem) and Paclitaxel (PTX) inhibit tumor growth in vivo 
to a greater extent than either single drug. Tumor volume as calculated by caliper 
tumor measurement.  Asterisks show significance between the Gem+PTX group and 
Control, Gem, and PTX groups. *p<0.05; **p<0.01. n=5 mice/group 
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Figure 36: 123B9-PTX inhibits tumor growth in vivo to a greater extent than PTX. 
Tumor volume as calculated by caliper tumor measurement. Asterisks show 
significance between the 123B9-PTX group and both the PTX and Control groups. 
*p<0.05; **p<0.01 n=5 mice/group 
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Figure 37: 123B9+PTX+Gem inhibit tumor growth in vivo to a greater extent than 
other treatment combinations. Tumor volume as calculated by caliper tumor 
measurement. Asterisks show significance between the 123B9+PTX+Gem group and 
Control, Gem, PTX, Gem+PTX, and 123B9+PTX groups. *p<0.05. n=5 mice/group 
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Discussion 
Though not overly efficacious, chemotherapy remains the mainstay of pancreatic 
cancer therapy.  There is a vital need to develop novel therapies that provide greater 
clinical benefit to patients.  This study evaluated modifications of both Gemcitabine and 
Paclitaxel against pancreatic cancer.  The strategy involved in these modifications 
revolved around developing conjugated drugs that are capable of specifically targeting 
the EphA2 receptor that is overexpressed on the surface of pancreatic cancer cells.  
Initial studies used Gemcitabine linked to the YNH peptide, which showed encouraging 
results.  This modified drug show greater tumor growth inhibition and prolonged survival 
in a xenograft model of pancreatic cancer.   
However, despite these results, the YNH was found to have less than optimal 
plasma stability.  The terminal tyrosine of this peptide, which is essential to specific 
EphA2 binding, was shown to be susceptible to aminopeptidases in the blood, leading 
to degradation.  This resulted in a half-life of only a few minutes.  A new peptide was 
subsequently created, 123B9, which replaced the terminal tyrosine with a synthetic 
tyrosine.  This new amino acid is resistant to aminopeptidase degradation while still 
retaining EphA2 specificity.  This translates into an increased drug half-life of 
approximately 4 hours.   
Paclitaxel is a commonly used chemotherapeutic drug most often used in breast, 
lung, ovarian, and AIDS-related sarcomas, though it is studied and sometimes used in 
combination in other cancer types as well.  Paclitaxel is a microtubule inhibitor and acts 
to stabilize polymerized microtubules.  Consequently, cells get stuck in the G2 and M 
phases of the cell cycle.  Solubility is a major issue with this drug.  It must be 
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administered in a solution with Cremophor and dehydrated ethanol.  These vehicles can 
have toxic effects on their own and have led to the inability to use higher doses of this 
chemotherapeutic drug in patients.  Furthermore, Cremophor-bound paclitaxel has a 
tendency to form micelles that trap the drug in the center, limiting its efficacy (138).   
Recently a novel formulation of Paclitaxel has been developed in which the drug 
is bound to albumin (nab-Paclitaxel).  High-pressure homogenization is used to combine 
albumin and paclitaxel.  Once injected, the drug is free to bind/unbind albumin or other 
molecules in the blood freely.  This results in more unbound drug in the circulation as 
compared to Cremophor-bound drug.  However, the nab-paclitaxel that is bound tends 
to be bound to albumin, which helps to facilitate its entry into tumor cells.  Nab-
Paclitaxel can use normal albumin transport mechanisms to gain entry.  Also, some 
albumin-binding proteins, such as SPARC, show high prevalence in the tumor 
microenvironment.  Whether or not this has clinical significance is still unclear (138).  In 
mouse studies, xenografted pancreatic tumors were found to have a 2.8 fold increase in 
intratumoral Gemcitabine concentration when the drug was administered in combination 
with nab-Paclitaxel.  They hypothesized that this may be due to nab-Paclitaxel-induced 
disruption of the stroma (139).  
A Phase 3 clinical study in patients with metastatic pancreatic cancer evaluated nab-
Paclitaxel + Gemcitabine versus Gemcitabine alone in a total of 861 patients.  The 
median survival was 8.5 months in the nab-paclitaxel + Gemcitabine group vs. 6.7 
months in the Gemcitabine group.  The survival rate at 1 year was 35% vs 22%; 9% vs 
4% at 2 years.  The response rate was 23% for combination group and 7% for 
Gemcitabine alone.  Toxicities included neutropenia, fatigue, and neuropathy (140).  
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These results encouraged the FDA to approve the combination of Gemcitabine and 
nab-Paclitaxel (Gem-Abraxane) for metastatic pancreatic cancer. 
In conclusion, these novel Ephrin-binding peptides represent an exciting new 
strategy in cancer drug development.  Of significant interest is that this technique is not 
limited to a single drug, but rather can be adapted to almost any drug, either by linking 
the drug of interest to a peptide or by using it in combination with the peptide.   We 
found in our studies with Paclitaxel that 123B9 showed greater tumor inhibition, 
presumably by helping to facilitate drug entry into cancer cells, even when it wasn’t 
actually linked with Paclitaxel.  In fact, when 123B9 was administered in conjunction 
with chemotherapy (Gemcitabine and Paclitaxel), but not actually as part of a modified 
drug, we saw the greatest efficacy.  We believe that this may be due to 123B9 
encouraging entry of both Paclitaxel and Gemcitabine.  Overall, these studies provide 
encouraging evidence that modifications of standard chemotherapeutic agents have the 
potential to improve clinical outcome in pancreatic cancer patients.   
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Chapter 4: Characterization of a novel double transgenic pancreatic 
adenocarcinoma mouse, ‘PanMetView (PMV) Mouse’, to non-invasively monitor 
tumor development and progression. 
 
Introduction 
Pancreatic cancer is an extremely deadly disease that lacks efficacious 
therapeutic options (1). There is a dire need to develop novel therapies for targeting this 
cancer. Translational research has focused on many strategies to target this cancer 
(141-145), but the study of such strategies is often impeded by the lack of appropriate 
preclinical models to validate efficacy. The creation of effective drugs or therapeutic 
strategies is a rigorous process that requires not only an understanding of the 
mechanism of action of a new drug, but also the ability to stringently test compounds in 
appropriate in vitro and in vivo settings. In vitro studies are fairly straightforward, as a 
variety of human pancreatic cancer cell lines have been established and are available to 
test experimental drugs (146). Testing new drugs in vivo, however, can be a daunting 
challenge if one does not have an appropriate preclinical model that recapitulates 
pancreatic cancer development and disease progression. Currently, there are a number 
of transgenic mouse models of pancreatic cancer that have been developed. They vary 
in a variety of ways, including the histological subtype of tumor developed, tumor 
latency, and the absence or presence of metastases (147,148). However, one missing 
component of all of these models is an efficient and simple global method to temporally 
monitor tumor development and growth. To perform sophisticated preclinical animal 
studies, one must be able to monitor tumor kinetics in a quantifiable way and use this 
strategy to define efficacy of newly developed therapies. Doing so in a non-invasive 
manner without having to sacrifice the mouse is particularly difficult and defining 
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approaches to obviate this problem will be transformative for preclinical testing of 
therapies.  
Bioluminescence imaging (BLI) is an optical imaging technique that is relatively 
inexpensive, user-friendly, and has wide-spectrum applicability. It is based on the ability 
of a cell that expresses luciferase to convert luciferin into oxyluciferin, which results in 
the release of photons that can be captured and processed into an image (149,150). 
Traditionally, this imaging modality has been used in xenograft studies, where cells that 
are engineered to express luciferase are injected subcutaneously or orthotopically into 
mice to create a tumor model with imaging capabilities. We are pioneering a strategy in 
which we can use BLI to image pancreatic tumors in the widely used pancreatic ductal 
adenocarcinoma (KPC) transgenic mouse model, or in principle any other solid tumor 
transgenic mouse model.  
Bioluminescence imaging (BLI) has been transformative for animal tumor studies 
permitting live non-invasive in vivo imaging to monitor tumor growth and progression 
using xenograft, orthotopic and metastasis models (149-154). For optimizing this type of 
imaging for transgenic animals, cancerous cells in the transgenic animals need to 
express a reporter gene, such as luciferase, under the control of a cancer-specific 
(cancer-selective) promoter. In previous collaborative studies with Dr. Martin G. Pomper 
(Johns Hopkins University) we demonstrated the utility of a reporter gene expressed 
under the control of a cancer-specific promoter, progression elevated gene-3 (PEG-
Prom), to image metastases (153) and study tumor progression.  
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CCN1 is a member of a large family of integrin-binding proteins that affects 
multiple signal transduction pathways in cells (155,156). In cancer, integrin-binding 
proteins are often dysregulated and can lead to changes in cell migration, adhesion, 
angiogenesis, and tumor growth. In pancreatic cancer, CCN1 mRNA and protein are 
elevated in tumor specimens and established pancreatic tumor cell lines (157). CCN1 is 
critical for EMT in this cancer type as well as for maintenance of stemness and 
aggressive behavior, with more aggressive cell lines expressing higher levels of CCN1 
(158). These pro-tumorigenic properties result in part through signaling via the Sonic 
hedgehog pathway (159,160). Silencing of CCN1 has also been shown to mitigate 
some of CCN1’s pro-cancer properties (158). Based on the cancer-selectivity of CCN1, 
we hypothesized that a CCN1-promoter-driven construct would be amenable for 
imaging tumors and metastases in vivo, similar to what we found with the PEG-Prom-
Luc-PEI construct (154). This possibility was verified using a CCN1-Prom-Luc-PEI 
construct, which when administered intravenously to nude mice containing primary and 
metastatic tumors was able to image these tumors/metastases (data not shown).  
The PDAC KPC transgenic mouse model, Pdx-1-Cre/K-rasLSL-G12D/p53flox/wt, 
has been used to study pancreatic cancer development and progression as well as 
therapeutic approaches for inhibiting these processes (128-132). As with all cancers, 
there is a multitude of genetic changes observed in PDAC that contribute to its 
development and progression. Activating K-ras mutations are found in over 90% of 
pancreatic cancers (1), making it a highly active contributor to the tumorigenic state. 
There is also a variety of tumor suppressors lost in high frequency in this disease, p53 
being one of them. This important gene is either deleted or functionally inactivated in 
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approximately 50-75% of PDAC (1). The KPC model of PDAC, which is broadly used in 
the pancreatic cancer field, mimics these human genetic changes in the mouse. A 
mutated form of K-ras, rendering it constitutively active (K-rasG12D), is introduced into the 
mouse with a Lox-Stop-Lox sequence located transcriptionally upstream (K-rasLSL-G12D). 
p53 alleles are floxed in these animals as well, either one or both alleles (p53fl/wt or 
p53fl/fl). Cre-mediated recombination results in the removal of the stop codon preceding 
the mutant K-ras and expression of this new genetic element, giving the tissue continual 
K-ras signaling. Additionally, Cre will remove one or both alleles of p53, resulting in full 
or partial loss of function of this critical tumor suppressor. Cre is introduced into the 
pancreas through the transcriptional control of a pancreatic-specific promoter, Pdx-1. 
When both alleles of p53 are deleted, tumors develop very rapidly and most animals do 
not live past 2 months of age, with a tumor latency of around 6 weeks. Animals that still 
retain one functioning p53 allele show longer tumor latency of around 21 weeks. This 
longer survival permits additional time to therapeutically intervene. p53 null animals, 
however, have more aggressive disease and can be useful for certain studies. As seen 
in human PDAC, this disease initially develops as a series of pre-invasive lesions, or 
Pancreatic Intraepithelial Neoplasms (PanINs) before eventually becoming an invasive 
cancer. The tumors show both local invasion and micrometastasis (133). 
We hypothesized that crossing these animals to a mouse that expresses 
luciferase under the control of a cancer-selective promoter, CCN1, would result in a 
mouse in which CCN1 would be transcriptionally activated in conjunction with tumor 
development in the pancreas and that the tumor cells would subsequently express 
luciferase, allowing them to be easily imaged via BLI (Fig. 38). We also aim to show that 
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this model is not only capable of detecting primary tumor development through BLI, but 
that metastatic lesions may also be visualized through this method. This is a significant 
advantage over traditional imaging methods, where the detection of metastasis is very 
difficult. These studies in general are highly significant, as they will provide a new 
platform for developing and using transgenic mice to study pancreatic, and theoretically 
other cancers, development and progression.  
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Figure 38: Development strategy for the PMV Mouse 
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Methods 
 
Characterization of ‘PanMetView’ (PMV) Mice 
Useful progeny PMV mice with the following genotypes were followed temporally by 
BLI: animals positive for the activating K-ras mutation, having either one or both alleles 
of p53 lost, positive for Pdx-1-Cre (which is responsible for the appropriate K-ras and 
p53 genetic changes), and also expressing CCN1-luc. We evaluated approximately 15-
20 mice. Mice were started on an imaging protocol beginning post-weaning, at around 4 
weeks of age. Animals were imaged using BLI one time per week and any signal on 
these images was quantified using Living Image software. Weekly imaging was followed 
over time and tumor kinetic graphs for each mouse based on these imaging studies 
were created. These mice were followed by BLI until they reached a moribund status.  
At this point, the mice were sacrificed and imaging done at different points throughout 
the necropsy to determine the origin of any signal seen in the animal. 
 
BLI of PMV Mice 
During imaging, PMV mice were placed in the imaging chamber and maintained with 
2% isoflurane gas anesthesia at a flow rate of approximately 0.5-1 L/min per mouse. 
Anesthetized mice were injected IP with 150 mg/kg body weight D-Luciferin (Xenogen 
Corporation, Alameda, CA). After approximately 10 min, mice were imaged using a 
charge-coupled-device (CCD) camera coupled to the Xenogen in vivo imaging (IVIS) 
imaging system (Caliper Life Sciences, Inc., Hopkinton, MA). The positive signal from 
 112 
background-subtracted images was analyzed by Living Image software for integrated 
density.  
Analysis of tumor tissues 
Criteria for euthanasia included loss of body mass, abdominal bloating and/or lack of 
grooming behavior.  Once mice reach a point where sacrifice is required, the animals 
were necropsied post-imaging. A second set of images was taken of individual organs 
to confirm the origin of the signal seen in the first set of images of the live animal.  
Tumor tissue was preserved in neutral buffered formalin and formalin fixed and 
sectioned for further evaluation.  
Immunohistochemistry 
Tumors were fixed in formalin, embedded in paraffin, and sectioned for staining.  
Staining was done as previously described (122) with anti-CCN1 (1:100, Abcam) per 
the manufacturer’s instructions. 
 
Results 
KPC mouse tumors express CCN1 
The KPC (Pdx-1-Cre/K-rasLSL-G12D/p53flox/wt) mouse is extensively used as a 
representative model for PDAC development and progression, and for therapeutic 
studies (128-132). This animal spontaneously develops precursor pancreatic lesions, 
PanINs, which progress and eventually develop into invasive disease. The model 
recapitulates the human condition, in which animals remain symptomatically unaffected 
by their disease until it is at a late stage of development. Tumors form as a result of 
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activated K-ras and functional loss of p53 in the pancreas, genetic changes also seen in 
a high percentage of human tumors.  Histological analysis shows extensive local 
invasion as well as metastasis in a subset of animals (133).  Immunohistochemistry 
(IHC) was used to monitor CCN1 expression in KPC mouse pancreatic tissue from 
control, p53+/-, and p53-/- animals. Control animals had limited basal CCN1 expression, 
with the exception of the islets of Langerhans, which showed mild CCN1 expression. 
Mice with p53+/- tumors had increased CCN1 expression and mice with p53-/- tumors, 
which are more aggressive, showed very high CCN1 expression (Fig. 39). To 
summarize, CCN1 expression correlates with both PDAC development and 
aggressiveness in the KPC mouse model. This data supports double transgenic GEMs 
that incorporate the CCN1-Luc promoter to identify tumors and metastases in the KPC 
PDAC mouse.  
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Figure 39: KPC mouse tumors highly express CCN1. CCN1 expression by IHC in 
sections of normal pancreas or pancreatic tumor from control and transgenic KPC mice. 
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CCN1-luc-KPC mice can monitor pancreatic tumor growth in vivo  
CCN1-luc mice were crossed with KPC mice to generated PanMetView (PMV) 
mice and several PMV mice have now been evaluated. After weaning, the mice were 
started on an imaging protocol, in which they were imaged by BLI one time per week.  
We evaluated both p53wt/fl and p53fl/fl mice.  This allowed us to study a number of 
additional factors, such as metastases. As has been previously shown (133), a portion 
of p53wt/fl mice will show metastases as well as local invasion. Most p53fl/fl mice though, 
because of the aggressive nature of their disease and their short lifespan, do not show 
distant metastasis, though evidence of local invasion is still demonstrated (133).   
PMV Mouse #41 (p53fl/fl): This mouse was imaged twice before it reached a moribund 
state requiring sacrifice. This animal showed strong abdominal signals, representing 
underlying tumor once the animal was necropsied.  As CCN1 is expressed in the testes, 
a signal in the testes in this animal was evident (Fig. 40). The strong signal from the 
testes often masks the signal from the pancreas. To overcome this issue, we covered 
the testes with dark paper blocking the signal, thereby allowing any signal originating in 
the pancreas or other CCN1-expressing tumor cells to be identified (Fig. 40). During 
necropsy, individual organs were imaged to determine the signal source.  As in the 
intact animal, the testes masked tumor expression, though when they were removed, 
the signal was clearly seen in the remaining organs. Most of the signal came from the 
pancreatic tumor, though signal was also detected in the spleen (which was encased in 
tumor upon opening the animal) and in the lung (Fig. 40B). Lung tissue will be analyzed 
to determine the presence of lung metastases.  
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Figure 40: Characterization of PMV Mouse #41 (p53fl/fl).   (A) Upper panel: intact 
mouse showing amplification of abdominal signal when testes are covered. Lower 
panel: exposed abdominal cavity showing actual pancreatic tumor and amplification of 
signal from that tumor following testes coverage. (B) Individual organ post necropsy of 
Mouse #41 showing specificity of signal 
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PMV Mouse #51 (p53fl/fl): This animal also showed strong abdominal signals, as well 
as signals from the testes (Fig. 41). This mouse was imaged for four weeks before 
sacrifice. Upon necropsy, a signal was also detected in the spleen and lung (Fig. 41B). 
This mouse had a large pancreatic tumor that displayed a strong and specific signal.  
 
PMV Mouse #48 (p53fl/wt): This animal still has one functioning allele of p53, which 
results in a mouse with a longer tumor latency.  Because of this, we were able to gather 
imaging data on this animal for approximately 2 months. The data show a clear increase 
in tumor growth that can be observed both through BLI and the quantification of these 
images (Fig. 42).   
 
PMV Mouse #225 (p53fl/fl):  Imaging of this mouse showed evidence of a pancreatic 
tumor as well as potential lung metastasis.  Individual organ imaging supported this 
(Fig.43).   
 
PMV Mouse #247 (p53fl/fl): Similar to previous mice evaluated, this mouse showed 
increasing signal over time, which paralleled its underlying tumor development. 
Evaluation of organs after sacrifice showed tumor specificity.  This mouse also showed 
evidence of metastasis in the lung as well as in the area ventral to the 
esophagus/trachea.  This latter region is atypical for this model (Fig 44).   
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Figure 41: Characterization of PMV Mouse #51 (p53fl/fl).   (A) BLI images and 
quantification. (B) BLI of organs post necropsy. Exposure = 10 seconds 
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Figure 42: Characterization of PMV Mouse #48 (p53fl/wt). BLI images and 
quantification. Exposure = 15 seconds.  
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Figure 43: Characterization of PMV Mouse #225 (p53fl/fl).  (A) BLI images. (B) BLI 
images of organs post-necropsy. 
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Figure 44: Characterization of PMV Mouse #247 (p53fl/fl).   (A) BLI images and 
quantification. (B) BLI images of organs post-necropsy. 
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PMV Mouse 271 (p53fl/fl) – female: Unlike the testes of male mice, female PMV mice 
do not show any strong non-specific signal.  The increasing signal seen is most likely 
indicative of underlying tumor (Fig. 45).   
 
PMV Mouse 261 (p53fl/fl) – female:  This mouse did not show significant non-specific 
signal throughout imaging.  Upon necropsy, pancreatic tumor and lung showed 
expression, as well as minor expression in the reproductive tract.  However, though 
there is some background signal in the reproductive tract, removing these organs do not 
significantly enhance the signal in the pancreas and lung, which supports that the signal 
is only mild and not affecting the ability to detect the pancreatic tumor (Fig. 46). 
 
PMV Mouse 249 (p53fl/fl) – female:  This mouse showed specific signal in the 
pancreas/pancreatic tumor.  There does not appear to be any evidence of metastasis in 
this animal – the lungs were negative for expression (Fig. 47).  
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Figure 45: Characterization of PMV Mouse #271 (p53fl/fl)(female).  BLI images.  
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Figure 46: Characterization of PMV Mouse #261 (p53fl/fl)(female).   (A) BLI images. 
(B) BLI images of organs post-necropsy. 
B 
A 
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Figure 47: Characterization of PMV Mouse #249 (p53fl/fl)(female).   (A) BLI images. 
(B) Imaging of opened abdominal cavity and organs post necropsy.  
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A PMV pancreatic tumor-derived cell line retains luciferase expression in vitro 
 
A cell line was established in vitro from a pancreatic tumor that developed in 
PMV Mouse #48. After being established in culture, cells (1 x 106) were injected 
bilaterally into the flanks of three athymic nude mice.  Imaging at 10 days post-injection 
showed that these cells retained luciferase activity. Luciferase expression was detected 
by BLI in these tumors (Fig. 48). The tumors developed very rapidly and showed a more 
aggressive phenotype as compared to human pancreatic cancer cell lines similarly 
injected into nude mice (i.e., MIA-PaCa-2 and PANC-1 cells) (data not shown).  These 
cells were also injected intraperitoneally into immune-competent Pdx-1-Cre-negative/K-
rasLSL-G12D/p53 mice, where they showed luciferase expression approximately 1 week 
after injection (Fig. 48). This last set of conditions was also repeated with bilateral flank 
injections.  These mice form rapid tumors that can be imaged by BLI and make for a 
very useful syngeneic mouse model (Fig. 48).  
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Figure 48: PMV-derived cells retain luciferase activity in vitro and when 
reintroduced in vivo 
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Discussion 
 
The KPC model (Pdx-1-Cre/K-rasLSL-G12D/p53flox/wt) combines a mutated form of 
K-ras with loss of either one or both alleles of p53 specifically in pancreatic tissue, which 
is accomplished through the use of a pancreatic specific promoter, Pdx-1. The result is 
a mouse that develops spontaneous pancreatic ductal adenocarcinoma (PDAC) at 
approximately 21 weeks of age (133). 
Current studies utilizing the KPC model highlight the need for improved 
monitoring of tumors. Many studies either wait until an animal is sacrificed to collect 
data on therapeutic efficacy (130,132) or use more sophisticated imaging techniques 
that require additional training and cost (129,131). To enhance the utility of the KPC 
transgenic mouse model we developed CCN1-Prom-Luc (CCN1-Luc) transgenic mice, 
which display de novo Luciferase expression in the testes, but no other organ. Crossing 
CCN1-Luc mice with PDAC (KPC; Pdx-1-Cre/K-rasLSL-G12D/p53flox/wt) mice generated 
double transgenic mice (CCN1-luc/Pdx-1-Cre/K-rasLSL-G12D/p53flox/wt mice, PanMetView 
or PMV). Primary tumors and metastases in PMV mice display luciferase expression as 
pancreatic cancers develop and metastasize. Confirming the utility of PMV mice for 
detecting and monitoring progression and therapy of pancreatic cancer has the potential 
to transform how this PDAC animal model is used to study pancreatic cancer. 
Additionally, this approach also holds significant promise as a potentially universal 
strategy for converting any transgenic animal into a reporter-driven PanMetView (PMV) 
mouse by crossing it with CCN1-Prom-Luc transgenic mice.     
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All animals imaged thus far have shown expression in the testes, which was 
expected due to CCN1 expression in this organ. The signal in the testes is frequently 
strong enough that it overshadows any other signals, which can be problematic. 
However, because the anatomical location of this organ is distant from that of the 
pancreas, we can use black paper to physically cover parts of the mouse to block such 
signals. When one utilizes this approach, non-testes signals intensify. This has been a 
useful technique in identifying the presence of pancreatic tumors. Future studies will 
include alternate means of genetic and chemical modification to reduce or eliminate this 
signal in male animals. In the context of female animals, no non-specific signals are 
detected.  
As with many transgenic models of human cancer, the KPC models shows great 
variability from animal to animal with respect to the precise time of tumor development, 
as well as the kinetics of tumor growth. This problem is also seen in the human disease 
state. PDAC is a particularly variable cancer, as some patients can survive for longer 
periods of time with a high tumor volume, while other patients die with relatively small 
tumors. The location of the tumor, as well as the growth parameters and invasive nature 
of the tumor, all of which can affect the normal functioning of surrounding organs and 
vessels, contributes to this end point. Because of this variability, one cannot make 
assumptions on the therapeutic efficacy of a drug based on a group of these mice. 
Rather, each mouse needs to be evaluated individually so as to be able to accurately 
assess the outcome of therapy on a particular tumor. The ability to generate individual 
tumor kinetic curves with the PMV mouse will be a great advantage to developing highly 
impactful preclinical studies.   
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Our PMV model provides a way of non-invasively monitoring KPC tumor 
progression that improves the quality of studies relying on survival and/or post-mortem 
evaluation for data. Additionally, our PMV model also provides an imaging strategy that 
is relatively inexpensive, easy to use, and has wide levels of applicability, which gives it 
advantages over other imaging modalities. Furthermore, the ability to detect metastasis 
is possible using the PMV system, which is not a possibility with imaging methods, such 
as ultrasound. The PMV model is transformative and can be rapidly used to test for 
effective therapies of PDAC in an immune-competent transgenic mouse. Showing the 
therapeutic efficacy of a novel drug or compound in immune-competent transgenic pre-
clinical models of disease is critical for developing improved therapies for patients with 
PDAC. Our proposed studies will allow for a significant gain in utility of an accepted 
PDAC model for the study of pancreatic cancer development, progression and therapy.  
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Chapter 5: Summary and Future Perspectives 
 
Despite years of research, pancreatic cancer remains an extremely deadly 
disease with very few therapeutic options.  The poor prognosis results from both a delay 
in diagnosis, due to a lack of telling symptoms, as well as a significant amount of 
diverse genetic changes, which contribute to its intrinsic aggressive nature and 
resistance to standard therapies.  This body of work has focused on exploring novel 
avenues of therapeutic targeting in pancreatic cancer.  This includes the identification 
and targeting of novel targets, the modification of current therapies to improve efficacy, 
and the creation of improved methods of studying potential therapies in preclinical work.  
Chapter 2 describes this first technique, in which the anti-apoptotic Bcl-2 proteins 
were hypothesized to be a potential therapeutic target in pancreatic cancer. Sabutoclax, 
a small molecule BH3 mimetic, binds to and inhibits the function of the anti-apoptotic 
Bcl-2 proteins.  In this study, we aimed to evaluate the efficacy of Sabutoclax and 
Minocycline, a synthetic tetracycline and understudied potential anti-cancer agent in the 
treatment of pancreatic cancer.  We used a variety of in vitro techniques including 
proliferation and cell death assays, cell cycle analysis, and western blotting to 
accomplish this in multiple pancreatic cancer cell lines.  Several mouse models were 
also used to scrutinize these drugs in vivo, including the commonly used KPC mouse 
model.  Sabutoclax induced growth arrest and apoptosis in pancreatic cancer cells and 
synergized with Minocycline.  Together, these two drugs showed profound cytotoxicity 
that was caspase-dependent and occurred through the mitochondrial pathway of 
apoptosis.  Furthermore, the toxicity induced by Sabutoclax and Minocycline was reliant 
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upon loss of phosphorylated Stat3, with reintroduction of activated Stat3 capable of 
rescuing cells from toxicity.  In vivo work showed that this combination inhibited tumor 
growth in immune-deficient and immune-competent models and prolonged survival in 
the KPC transgenic mouse.  In conclusion, Sabutoclax and Minocycline promoted 
profound cytotoxicity in pancreatic cancer, both in vitro and in multiple in vivo animal 
models providing significant survival benefits.  These drugs offer a novel and exciting 
direction for developing effective therapeutic options for patients with this devastating 
disease.   
Chapter 3 introduced a novel strategy of taking a commonly used 
chemotherapeutic drug, Gemcitabine, and altering it in an attempt to increase efficacy.  
Despite being used extensively in the treatment of pancreatic cancer, Gemcitabine 
delivers minimal survival results at best.  This is partly due to intrinsic cellular resistance 
mechanisms that lead to either decreased uptake of the drug, improper metabolism and 
utilization, or increased output of the drug.  We showed that linking Gemcitabine to a 
peptide that specifically targets the EphrinA2 receptor, which is overexpressed on 
pancreatic cancer cell surfaces, leads to an increased uptake of the drug through an 
alternate delivery mechanism. More recent studies using a synthetic peptide, 123B9, 
tethered to Paclitaxel also showed encouraging results, with the drug conjugate 
demonstrating better efficacy as compared to Paclitaxel alone.  This modified drug also 
showed exciting results when used in combination with Gemcitabine.  These studies 
and this combination in particular are extremely clinically relevant due to the recent 
approval of Gemcitabine-Abraxane (nab-Paclitaxel) as the first line treatment for 
metastatic pancreatic cancer.  123B9 demonstrates increased plasma stability as 
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compared to YNH, which translates to greater clinical potential.   We found that in vivo, 
these novel drug conjugates inhibit tumor growth and lead to a prolonged survival.  
Importantly, the addition of the peptide does not confer any additional toxicity to the 
drug and holds significant clinical potential.  123B9-Gemcitabine conjugates have been 
made as well and studies with this drug are in progress.   
Finally, in Chapter 4 we introduce an exciting and novel preclinical mouse model 
that builds off of the existing and commonly used KPC transgenic mouse model of 
pancreatic cancer.  Though this model accurately recapitulates the human disease, 
monitoring tumor development and growth remains a difficult obstacle and hinders the 
ability of researchers to perform sophisticated studies with this animal.  Many imaging 
techniques, such as ultrasound or PET, though useful for monitoring tumor in these 
mice, can be expensive, require extensive training, and take significant time.  Most 
importantly, these methods cannot detect tumor metastasis, an important feature of this 
disease.  We hypothesized that crossing KPC mice to a mouse that expresses a 
Luciferase reporter gene under the control of a cancer specific promoter, CCN1, would 
allow us to create a mouse in which the promoter was turned on during cancer 
development in the pancreas and lead to luciferase expression in all transformed cells.  
Luciferase expression in vivo can be easily monitored via BLI and provides a rapid 
result image that can be easily quantified to follow tumor development.  Of significance 
is the ability to monitor metastasis in this mouse.  As tumor cells express luciferase, 
metastatic lesions that would otherwise be too small to see via other imaging modalities 
show expression using BLI and provide a novel technique of monitoring the metastatic 
process in the KPC model.    
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Moving forward, these studies provide important beginnings for novel avenues of 
therapeutic exploration in pancreatic cancer.  The Bcl-2 family of proteins is 
understudied as a therapeutic target in pancreatic cancer and our data provide solid 
evidence that compounds such as Sabutoclax deserve further attention and study.    
From a clinical perspective, there is significant potential in targeting Mcl-1 for 
suppression.  The Bcl-2 anti-apoptotic proteins continue to present roadblocks in the 
treatment of cancers when using conventional chemotherapeutics.  Their 
overexpression becomes vital to the survival of many types of tumors.  Mcl-1, in 
particular, plays a significant role in the ability of cancers not only to survive, but also to 
resist treatment with chemotherapy and radiation.  In vitro experiments using Mcl-1 ASO 
emphasize the anti-tumor potential of targeting Mcl-1 both alone and in combination 
with other therapeutic agents.   
Developing an optimal cancer therapeutic for any tumor indication is clearly an 
imprecise process and very difficult. To achieve this objective, a number of issues must 
be considered one of which is the best approach to use. What technique would be most 
appropriate to target Mcl-1?  Since the ultimate aim is to develop a viable clinical 
therapy, it is important to consider the translational potential of any strategy.  Some 
strategies, like those that employ ASO, may be very effective in in vitro and preclinical 
experimental settings, but are not easily translated into the clinic.  In contrast, other 
methodologies, like the use of small molecule antagonists, may hold greater potential 
for clinical translation if an effective drug level can be attained without unacceptable 
toxicity.  Ultimately, the real potential of these compounds may lie in combination 
therapies, as we have demonstrated with Sabutoclax and Minocycline.   
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Another important consideration in developing an appropriate cancer therapeutic 
is the target itself.  There is abundant evidence in almost every cancer type that the Bcl-
2 anti-apoptotic proteins play a significant role to some extent in that cancer’s survival.  
Many studies provide evidence that targeting these anti-apoptotic proteins individually 
might be a promising treatment strategy. What is only recently becoming abundantly 
evident is the importance of interactions between these proteins in both normal and 
cancer cells. Protein:protein interactions are complex and the interplay between multiple 
proteins in these complexes and their consequences on cellular phenotype are active 
areas of investigation.  It is also important that when targeting these proteins to block 
their interactions off-target toxicity in normal cells and tissues is not promoted.  
Our studies with Sabutoclax and the combination of Sabutoclax and Minocycline 
may demonstrate the importance of such interactions through the potent loss of Stat3 
activation observed with this treatment.  Though the effect of Stat3 activation on Mcl-1 is 
clearly defined, the reverse situation is not.  Why does targeting downstream proteins 
like Mcl-1 lead to such potent upstream signaling changes?  Research into the literature 
on Stat3 regulation and potential feedback loops through Mcl-1 or Bcl-xL reveal very 
little.  Known interactions between the anti-apoptotic Bcl-2 proteins with proteins outside 
of this family do not play any known role in Stat3 activation.  However, due to the low 
dose of Sabutoclax that is being used, we feel strongly that these signaling changes are 
not reflective of off-target effects of the drug.  Rather, we have hypothesized that 
Sabutoclax may be interrupting a protein:protein interaction between Mcl-1 or one of the 
other antiapoptotic proteins and a yet unidentified second protein.  Our theory is that 
disruption of this interaction may release this second protein, which we hypothesize to 
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have either direct or indirect effects on Stat3 activation.  Recent studies by Maurizio 
Pellecchia’s group have provided evidence that may support this hypothesis (161).  
Using Sabutoclax as competition, they screened a 12-residue phage display library for 
peptides that bound Mcl-1, specifically the BH3 binding domain.  Their studies resulted 
in the identification of a novel Mcl-1 protein-binding motif and subsequently, novel 
potential protein interaction partners that display this motif.  This is significant, especially 
for our studies, as it sheds light on previously unknown Mcl-1 binding partners.  As we 
have hypothesized that such an interaction may be mechanistically responsible for the 
effects we have observed with Sabutoclax and Minocycline, this new information 
provides a beneficial point from which to develop future studies.   
In continuing efforts to develop new and better BH3 mimetics, understanding 
potential mechanisms of resistance is critical.  Resistance remains a significant problem 
in cancer therapy in general, and understanding how it develops may be of great value 
in designing approaches to circumvent this major barrier to cure. Considering that the 
Bcl-2 family of anti-apoptotic proteins plays a critical role in cancer maintenance and 
resistance, these proteins represent high-priority targets for the next generation of 
combinatorial therapies for neoplastic diseases. 
The development of novel targeted agents, however, is only as useful as the 
model with which you can test them.  Our studies characterizing the PMV mouse are 
very exciting, as this strategy elevates the sophistication and utility of the KPC 
transgenic mouse model by adding a non-invasive imaging component.  This mouse will 
soon be used in therapeutic studies that we hope will produce beneficial preclinical 
data.  Future studies will focus not only on using these mice for preclinical work, but 
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also on improving the model even more.  To enhance further the value of the PMV 
mouse we intend to create a transgenic mouse producing the human secreted 
embryonic alkaline phosphatase (SEAP) protein selectively in cancerous pancreatic 
tissue by regulation through a cancer-selective promoter, CCN1-Prom. Crossing 
tCCN1-SEAP animals with PMV animals will produce compound ‘Pancreatic Biomarker 
Metastasis View’ (PBMV) mice. This model would not only have a built-in imaging 
system to non-invasively monitor tumor development and growth, but it would also have 
a built-in biomarker detection system to support and confirm imaging analyses non-
invasively. Early detection of tumors can be integral in managing the life of a patient 
with cancer, but in most situations achieving this objective can be problematic. Although 
imaging and other modalities have been used for this purpose for subsets of cancers, 
developing a more direct approach would be of added benefit. The ability to detect 
cancer biomarkers in a patient’s blood sample represents a valuable contribution to 
cancer detection.  Unfortunately, there has been limited success to date clinically due to 
sensitivity and specificity issues related to a given biomarker.  
SEAP transgenic mice have been previously engineered in which SEAP 
expression is under the control of an organ-specific promoter (162) and adenoviruses 
expressing SEAP under the control of cancer-specific promoters have been shown to 
be functional both in vitro and in vivo (163,164). However, a transgenic animal that 
expresses SEAP under the control of a cancer-specific promoter is a novel strategy that 
would further enhance the utility of our PMV mouse. Depending on the sensitivity of this 
system, it may even allow us to detect tumor initiation earlier than with BLI. This dual-
monitoring compound transgenic model would be unique and would significantly 
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enhance a variety of chemoprevention and therapeutic studies in pancreatic cancer 
transgenic as well as in other cancer transgenic mouse models.  
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